var title_f25_32_26112="Examination of finger DIP joint extension";
var content_f25_32_26112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal interphalangeal (DIP) joint extension should be evaluated independently of other finger movements, as depicted in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26112=[""].join("\n");
var outline_f25_32_26112=null;
var title_f25_32_26113="Chromosomal translocations";
var content_f25_32_26113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Chromosomal translocations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAhADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKiW5ga7ktVmiNzGiyPEHBdUYsFYjqASjgHvtPoaAJaK5/wAXa9daPDbwaPpv9ra1d+Ybax88QhxGhd2ZyDsXhUDEEb5YlJUPuGrpOoWur6VZalp8vnWV5ClxBJtK743UMpwQCMgjggGgC3RRRQAUVn+INZ07w9o13q2tXcVnp1qnmTTyHhR0HA5JJIAAySSAASRR4f1nTvEOjWmraLdxXmnXSeZDPGeGHQ8HkEEEEHBBBBAINAGhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVFc3MFrGsl1NHDGzpGGkYKC7sFRcnuWYKB3JA70XdzBZ2k11eTRQW0KNJLLK4VI0AyWYngAAEkmgCWiua8H+JZ9dkvIdQ0uXSruJIbqK2mctI1rMpMTyDaPLk3JKjR8lWiPJBVj0tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXEaN4zF/8AEC/0Uz2TWg8yK3VHBmEsITzN4zwCXYDj/lixzyK3/GepT6P4P13U7QIbmysJ7mIOMrvSNmGR6ZAoA2KK4Oz8XXls+qwah5TzW5gNslzDJZvKJNw+7hywypA2gkkEY4yW2/jh7ma3uxGltamyumkt7ljHieK6SDBYruHzFgBtycj5c8UAd9RXF2Pjaa/EFvaaSx1KS4mtjDLK0SK0aK5O50D4KsMZQHJ6Y5qzpHi860LWbS7AvZtaW95cSzTCMwpMu9Qq4O4heSMjtgk8UAdXRXB6f8Q1voomi0mfddiI2WSwWTzGACyMUARgCGIXeMZwSRit3wXqN7qem3cupiNbiO+uYNsZyqqkrKADgZwAOcDNAG/RRRQAUUUUAFFFFABRRRQAV5V4E/0jxP4Y1Y/M2s6ZrOqh25kaKe7sngWQ/wB5IDDHjJCiMKCVUV6rXlXw4/5pZ/2Jk3/uNoA6vQv+Jj478TX8v/MO8jSIEb5tn7pLmSRT/D5n2iJWUdfs6Ek8BT4T/wDJLPBv/YFsv/RCVlaXq/8AZXhzxr4oWDz5Z9Tu3hsQ+1pZbfbZRwq2DlpXtV2gLnMoUBiMt1XhPSP+Ef8ACujaN5/2j+zrKGz87Zs8zy0CbtuTjOM4ycetAGrXz0PiRreoftZWvhe01SI+HLVJrRre32skr/ZTK5kPOZFlQLxjbsK8Zfd9C181+Dfh1/Zvxk03x7/anm/2p4m1iz+w/Z8eVgX43eZu5/1PTaPvdeOQCX9tjxBPZeEdB0KDzUj1O6knmkSUqGSEL+7ZR94FpVbk8GMcHgjoP2PdVn1H4Pi1nSJY9N1Ce0hKAgshCzZbJ5O6ZhxjgD3Jz/jF8I/+FqfFOb/id/2V/ZujWf8Ay6ef5nmT3f8AtrjHl++c9sV3X7P3h+Dw58K9KtLYxSxyvPcpdpEIzeRPK5hnZeSC0PlHDHcowp+7gAHotFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlXxc/4mMPi+GT/AFWi+Eru5RG+ZXlukmRZAP4WjS2lUNySLhx8ozu6v4l/v/DK6aPn/tW9tdPkgH3p4JZ0Fyijr/x7+eSV5VVZgRtyPBf2oPiBqvg/xpqWkaZb2Mtt4h8OQ2l01wjs6J5l2uYyGABxK3UHoPx9P/aE8Xf8IJo/hfxJ9i+3/YtZ/wCPfzfK377O6j+9tbGN+eh6UAdXpv8AyVPxD/2BdM/9H39dVXkvwJ8YT/Ee61/xg2mxaZbOltpKW4uTO5eAzSs5OxQARdIAOfun2r1qgDyrwR8Wf+Er+MXibwdb6Z5NlpEMm26d/wB48sMwilyoyNpLjbzkBCT97CRftHfE2f4c+EbcaR5X9u6o7Q2rSKWEKKPnmxgqxXcgCsRy4OGCkHwX9in/AJKnqv8A2BZf/R8FaH7bmqzzeNPD2kMkQtrXT2u0YA7y8sjKwJzjAECY47nrxgA7/wDZA8b6/wCKdG8Qad4hv5dQGlvA9vcXDF58S+aWVnJywBTIzyMkZwFA+ha8A/Yy8Pf2d8OL7WZrXy59WvW2TeZnzYIhsX5c4XEhnHQE+4217/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZsOh6dDDYxRW+1bKdrmD52ykjBwzZzkk+Y+c5zuNDaJp7+Hn0N4WfTHtmtGieV2LRFdpUuTu6E85z71pUUAYDeEdHYP5kNzJKzI/nyXs7TKUzt2yl96gbm4BA+ZvU0g8G6ELZYPsT7FEmCbiUsC8wnZg27cG80Bw2cggYIroKKAMfT/AA1pWn3CT21vJ56SvMJJJ5JGLuiozEsxJyqqOfSo7Xwpo9o1kbS3mg+yQQ20YiuZUBji/wBWrgNiQLzjfnqfU1uUUAc+ng/RUtjbpBcLb/LsiF5Nsh2sGXyhvxFggY2bcYwOK09J0y00m1a3sY2SJpHmbfI0jM7sWZizEkkkk9au0UAFFFFABRRRQAUUUUAFFFFABXlXw9/dal4DsW/1umeH9T0qYj7rS2tzZW8jL6qXiYqTgkEZAPA9VrxrXdK1eXx7/wAIv4d1mLQL4PdeILLUYoorp4raTykntniYhiJLmWabLZT5IwuSuIgDQ0v/AE3S9F0YfMt54t1K5nCcyJFbX91cCQei+fHbIzEYxKF4ZlNeq1518Ko01SOHVfIsbS20q1OiadY2l412tvCrAmTzWVCwmRLV03A/u0jcN+9YV6LQAV5Vp/8AottoM9x+7TTvGeo/awfvQ/aZL2ODcvX52u7Yjj7sqv8Ad+avVa8l8YtPa+ItW8PWccT6t4g1Cy1bSZLmQxQG4giDMj4VmaOP+zo2coMn7SifJkSUAW/E9zPJJ8Q7uymltL6RLHwvaPG5Ux3EihorjeMFQJNSQHAJURFhuJCj0q0toLO0htbOGKC2hRY4ookCpGgGAqgcAAAAAV5r4Vtp9Y8UXdpqEMqy6dqD6nrG5D5U16yhbSFG+5LHFbrE+cK25bWQhXMij0+gAooooAKKKKACiiigAooooAKKKKACiiigAooooA+Nf22dPuovH2hak8WLK40z7PFJuHzSRyuzjGcjAlj5Iwd3HQ40P2ufEE+veC/hpqC+Za22q2suoPaCUsiu0cDLnoGKiRwGwPvHpk16h+1r4Yj134VTairW0V3osy3aSShFZoz8jxq7Ebc7lbAyWMaqASRj5g+CdrY+LPib4S0vxXf2yaXY5jt4LhVCz4keZLf7hVt8sjZD43AlQclRQB9n/BHwe/gb4aaPo91HEmo7DcXpRFUmaQ7mVipIYoCI92TkIMYGAO6oooA+MPg5A/wz/ahu/DcxihtJ3n01ZLyRS5hcCW3IZSF8x9kIxj+MjAJ4z/jHY6x8WP2iNS0Tw0ft32PZYxuyeXHaxxAecZG252rM0vzHJJIC5yoOh+09eQePvjBp/hzwjpkt9rtkn2CaeGUOJ3zv8sAHaoizJuY4wS4bAQGovgNrt18KPit/wiXifw5bJqWpTQ2U10jiS5tzLsMShg5jMRLKWC4PzAknYFoA+v8AwpoNj4X8OadomlR7LKxhWGPIUM2By7bQAWY5ZjgZJJ71q0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeNSaRaePbrTYtXiikg197rXEneGOb/AES2KQ2SRrIrbAVuY7ghsjc0yMm2Z0HovxC1C60jwD4l1LT5fJvbPTLm4gk2htkiRMynBBBwQOCCKyvDmnWum+P7zTbOLZZaV4f063so2Yv9njaW6VgpYkjcIIdxzlvLTOdowAYngOd4F+HmpSCKGPXPDkVlcGKNUSS4jiSe3RUUYjAjN+w2hV7H/lmK9QryrSP9H+Efww1NOZ7D+xvKU/dP2hEs33DrxHdSEYI+YKTkAg+q0AFeS+L4E8U+Imy0sU39oL4f0e8gkaNrY+V9ovrmKZCCJCkTwAfMFktyrfLJKo9aryr4Wf8AEx1LRL5v3cqeH/7VmA5V5dWuTcSKv91Y3tmCg7iRIMnK5YAm8PypYN4X1K2gitQdQvPD2pOhbypgktwqzuWJYyPcwrsMjuQ15IuXeTcfT68qn/dfCLX7/r/ZWs6jq+z/AJ6/ZNWmufLz/Dv8nbu5xuzg4wfVaACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5g/bW8XyW9hovhKzudv2rN9fRrvVjGp2wgn7rKWEhKnJzGh44z4/8dfBdr8LfGHh7TdAu7n7XDpkN5JfBykj3PnS/vVwfkxsUKAeAo5Jyx6v4s6hH4k/ay0yyu5bbUdNttT07TliKpJGI98ZlibAw37x5QwbJySp6YB+2t/yVPSv+wLF/wCj56APq/4a+Jk8Y+AtD19WiaS9tVecRIyIsw+WVVDc4EiuByenU9a0PFmr/wDCP+FdZ1nyPtH9nWU155O/Z5nloX27sHGcYzg49K8//Zc/5IT4Z/7ev/SqWj9qP/khPib/ALdf/SqKgDxr9h/SoJtf8Vauzyi5tLWC0RQRsKSuzMSMZyDAmOe568Y8b+NeoXWp/FzxfPfS+bKmpz26ttC4jicxxjgDoiKM9TjJyea+mf2J7aBfhtrN0sMQuZNWeN5Qo3siwxFVJ6kAu5A7bj6mvC/2ptGfSPjTrL/ZIra21BIb2ARhQJAyBXfC9CZUlznBJye+SAfcnhPV/wDhIPCujaz5H2f+0bKG88nfv8vzED7d2BnGcZwM+latcL8DPD8/hj4S+GdLvPNFylr58qSxGJ4nlZpTGynkFTIVOf7vQdB3VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/Ev/AJFyz/7DWk/+nG3o8K/6R4v8aXU3zTw3tvp8bdMQJaQzKmOnEl1O2evz4zgKBa8e6fdal4Tvo9Ni87UoPLvbKIsFWW5gkWaFGJIG1pI0DcjgnkdRV+G/+laFcay3zPrV7PqCzdPOgZtlq+3+H/RktxjAPHzDduoA5SL918KNIsV/1WmeILLSoSfvNFa6xHbxs3qxSJSxGASTgAcD1WuFuvC2q/2/aWdobE+DjqA1a4ilmcXC3G+WYogCcxm5ME2S4IIkXlCqL3VAHNfE25ns/ht4surOaWC5g0m7kilicq8brC5DKRyCCAQRVTQraCz+JOt2tnDFBbQ6FpccUUShUjQTXwCqBwAAAABVv4m20958NvFlrZwyz3M+k3ccUUSFnkdoXAVQOSSSAAKqeC7mDW/EXiXX7SaK4tJXt9Os7m3YPBcW8Mfmb1YZDETXNwhIOP3YXAKsSAc1e/8AJCfH3/cx/wDpVd16rXnXjPQ9XMms6ZpOnS3+l+LHVdRuFljRtPBWC2mYbmG4NbKzLhWKyR8h1cBPRaAKv9oWo1X+zWl23ph+0LGykb4920lSRhtp27gCSu9M43rm1WfrelQavapFM8sM0Tia3uYSBLbygECRCQRnBIIIKsrMrBlZlNXRNVne7fStZSKHWIkMgMYIiu4gQPOhyScZKhkJLRswBLKyO4BtUUUUAFFFFABRRRQAUUUUAFFFVdU1C10qwlvL+XyrePAJClmZiQqqqgEszMQqqoJYkAAkgUAS3NzBaxrJdTRwxs6RhpGCgu7BUXJ7lmCgdyQO9S1z+lafdX9/FrOvReVcR5NlYFgy2SkEFmIJDTspIZgSEBKISC7y9BQB8TfD62guv2xbqO6himjGu6nIFkQMA6CdkbB7hlDA9iAR0rf/AG3PD88ev+HvEamV7ae1bT3xEdkTxu0i5fplxK+F4/1ZPPOOrs/hvqukftcR67p2ly/8I/Ok2pSXSbzHG8sEkbqztx5hmYtsUnCuDgAHHovx/wDh7ffEnwPDpOlXlta3tvex3kZuQ3lyYV0KllBK8SE5weVAxzkAHNfse6VPp3wfF1O8TR6lqE93CEJJVAFhw2Rwd0LHjPBHuB7Jq2n2ur6Ve6bqEXnWV5C9vPHuK743UqwyCCMgnkEGsX4b+E4PA3gnSvDlrcy3cdkjAzyKFMjs7O5wOg3McDnAwCT1PS0AcL8G/h5B8M/CL6LBqEuoyS3T3c07xiMF2CqAqAnACovUnnJ4yANXxx4F8N+ObW2t/FWlR38ds5khJd43jJGDh0IbB4yM4OASOBjpaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqre6hZ2MtrHeXUMEl1J5MCyOFMj4ztX1PB4oAtUVDbXMF0rtbSpKqSNExU5wynDKfcEEVNQAVFbW0FrG0drDHDGzvIVjUKC7sWdsDuWYsT3JJ71LVe/vbfT7Y3F5KIoQyJuIJ+ZmCqOPUkD8aALFFFFABWfrelQavapFM8sM0Tia3uYSBLbygECRCQRnBIIIKsrMrBlZlOhRQBlaFe303n2mr23l39rtDzRRsLe5U52yRk5xnBzGSWQjBLKUkfVoooAKKKKACiiigAooooAqatqFrpGlXupahL5NlZwvcTybS2yNFLMcAEnAB4AJrK0rT7q/v4tZ16LyriPJsrAsGWyUggsxBIadlJDMCQgJRCQXeXoKKACiiigAoopHZURnchVUZJPYUALRVGx1jTr+O0eyvbedLtGkt2jcMJVUgMVx1AyM/Wrx6dcUAFFFFABRVeyvbe+SV7WQSLHK8LkAjDoxVh+BBFWKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKzvEGqLo2lveNE8zeZHDHEhAMkkkixouTwMs6jPbOaANGuW8a6DLr13osYVhbwzSvLMrANATA4R1z/EHKkYzggGs/W/E+taTqY8/TYGih025vbi3S5BBETR/MjlASdrMApAyTyR1q3eeMzDdX6Q6XPNBay29v5/mookln8sRIATkZMqgkjA689KAOYtfD+utYRvrejfbXd9QZ7SC4jCxzyzK0U4LOBjAfBzvTcMDJOLlx4U1aWw1x7nz7nVJEtYreZboqHCxRLKyjcApLK+SQCfyrb/AOEtuWvBpsOlK+ri4ktZITdYiRkiSbPmbclSkiEfLnJwQOaq2vj4T2ttOdMdPt9tbXVgnnAmVZ3CKH4whBZScFuD6jFAFVfCt1Z6tPc6bYRxeVrUUtmVkVRHaG2jEoUZ+VTKZdygZJ5weDWJZeGNfZbktpklsbiO0aeEG3jiadLpHdkCMSQF3fM5LHGPQV01747+xvHFcafHBMk0kFzJPc7LeJ02HaJduCzCRWUMEyAckEYq1L4yEUjSyWDf2e9xdWkE4lBaSa3WUuCmPlU+RKAcn7vIGRkA62iuHPji5RZHn0bZHDBa3kpF0CVt7h2RCBt5cFHyvTA4Y5xVzRvGUeq66bGCxm+zNLNDHcAMfmiJDFxt2qpKttIYk8ZAJoA6yiiigCG8llhtnkt4GuJVHyxKwUtz6niuc0/xlaSaYNR1WFtKs3ma2ikuJUPmSKzqVAUnnKNj17V1Nc1a+F/IstJt/tm77BqMt/u8rHmbzMdnXjHndefu9OeAC8PEel/aWga4eNwjSBpYJERwq7m2uyhWIHJAJIqGPxboktvLNHe7kjMYwIX3P5hIjKLt3OGwdpUEHBx0NYVz4Ce41iS9l1GFyZLp1ke0LXG2ZHXyzKX5RN/yqFAwoHXmrN14L84S4uraQvY2VmFuLUyKPs7TNv4dSCfO4wQVK9TmgC+3i7T4754pSyW4tYrhZSjbnMkjoIxHjduynTGecY4qxL4o0eO2tpzeb0uA5jEcTu2EO1yVUEqFPDEgbTwcGsGLwNcRS2VyusvJf2cUKRTTxNIN6PKcsC+5lKzMoBbIAB3E81ZtPCd5p9zHe6dqsKagyzi5ea0Mkchll80lUEgKYYkD5jx1yeaANHU/Fel6cl+Z3uPMs4JZ2T7O6mRYxlxGzAK5HHQnGecU6PxXo7i1zdMhuFVlDQuNgZiq7zjCZYEDdjJHGa56b4em41C4uLrUYpBKl3H5v2X/AEkpOGG1pS5yEBwoCgYHSpJPAsk18t5c3Wm3M7xRRT+dp7Mp8sna0Y835DtIByWGQCAOQQDai8UWVx4kt9ItA8zyJOzTBGEamJkVlDEbXOWIO0nBGDW/XKaL4Un03VbGc6jHLZ2K3KW8P2cq+2Z1b533kNt24GFGc88811dABRRRQAVBfRtLY3EcYy7xsoHqSK5DXvFOof8ACO69qOlWapa2QuIorppQXMsLFGPlkY271ZQd2TjOAOanm8YXEDSW0ukO+pLfpYC3huFZSXh85W3sFGNvB44IOM8ZAOTg8HeIbO3srXT4xBGNDnQOJgptr2SOJWQEHIDNHu3LnDFz6Z0x4ZvLu4hSLTLjTNFe/hkewFyqFEWGUSOfLcjDM0YKg87SSOTWz/wmhQCafTmSykmubSKUTBmae3WVpFK44X9xKA2TnbyBkZrHxxcosjz6NsjhgtbyUi6BK29w7IhA28uCj5XpgcMc4oAqJ4QmfVrWa4sBJEdYnM5eUNusTbyBEbJ5TzfKOz15I6msW88NeJJLDToP7OkNxZQxC1uIXtzJEyzMSryO25VCBMeXyeQT2rrJvGxiSS4/sq4mtHN1HaGBw8txJBv3L5eON3lvtwTnHIBIFFj4xl1BbaHTrK0vNQmE7+XBfAxqkPlh8uUBDZljAUqOTzgc0AavhKxudPtL9LuPy2l1G6nQbgco8rMp49QQfWtyuI/4T1Z4YrrT9MkuLFxZfvGmCOTd7RCAuDn5nXdkjAORnpTLrx+bfbbnTC+pq9wssCSsyKIWUHa4Qli29duVA65IxyAd1RUNjcreWVvcokkazRrIElXa6gjOGHY88ipqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqtqVhbanYy2d9EJbeQDcuSOhyCCOQQQCCOQRmrNFAGN/wjOlMkqywzTebby2jtNcyyM0UmN6lmYnnaOc5GOMVLJ4f0ySC9he2zHelDOPMbLFFVVIOcqQEXBGDkZ681qUUAZVl4e0yzmgmggfzoHeRJZJnkcs4CsWZmJYkAD5s4AGKx9U07wnpFpZ2eoCO2hjtI7SHdNIPKhiZSh3A5XawQhyQQQOc11tcn47j1LUIo9IttKurrSbtGW/mt5IQ5j6GFQ7r98Egt2GccnIALs3hHRp7MWssFw1ud4kQ3k2J95y3m/P+9z337uOOlSt4Y0hrue4a2cvN5hZTPJsBkGHZU3bVZgTlgAeTzya2VOVBIIJHQ9qWgDIk8N6TJHMj2mVmt4bRx5j8xQszRr17F2OepzzninWmgafZ6g95axzxSO7ymNbmUQ72+83lbtgJJJJ25ySepNatFABRRRQByni3V5LLWdOs5dVj0Wwmgmla9cJ80iFAsWZAVGQzMR1IXgjBrnNN1LUNP1N5Yr0yW95rd3atA0a7QFtZZg4P3s7ogMZxgnjPNenUUAeXSeJNZttE0251LXLe1ku9LbUYpRaoqzTbYytuAxOepOAQ7bvlI2mrt9rmuPf3LJd/Y1iv7Ky+zeSjhRPHFvJJGSymQkYIGRyCOK9EooA8uuvFWp28E0V1q8dmbb7esNzLDHm9lhm2RxEYAyVxlUAZs/LjBpbzxhrFrqOqJvWe9S1mmgsLby5lhKQhsTIMTKwbPOSrZAGCRXqFFAHnMfiHUJ7uCy07WkvrOa/htl1SOOJiQ8MryIu0bCylFIOON2DnBzSbxT4hs9Nju1nF/PNaahthMCgK9tMsayAKNxJBZmGcE/dC9K9TooA8nuPFmqw6U0x17TJLZJzmaC9tmuHTyydgZlEO7dztwCV9+T6fpk5utNtLgiQGWJJMSJsYZAPK9j7dqs0UAFFFFAGHP4V0ec3okt5jHebzPELmVYnL/ebyw20Me5AB5PPNWn0LTnvjeNb5uTcLdl97f61Y/LDYzj7nGOnfrzWlRQBit4Y0hrue4a2cvN5hZTPJsBkGHZU3bVZgTlgAeTzyaivdI0CJltrtIo3voYbFY3nZTKkJd40UZySu5zkcnvnFb9cr4ztbqfVPDtxZaRNfNZ3vnySxNCpjj8t1Iy7qeSynA9PpQAhsfC6a/NZ+YU1K4Mg8oXMqhXkHmP5Y3bUkYZc7MN1b3q4fCOjGLZ5FwHMjStMLyYTMzKqtul372BVEGCSMKo7CqN4mp6j4ztvtmk3S6Rp8nmWs0ckJWWUoVMr/ALwMFUOyhQpJJJPQV1tAGR/wjmk7HUWaqjPbSFVdlG63ZWhwAeApReBwcc5qO48L6TPIZTBLFMZZJvOguZYZA0mN+HRgwB2rlc4+UHHArbooAZBEsEMcUedkahVyxY4AwOTyfxp9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGZaa/pN5fvZWuo20t2jOhhWQbtyHa4A7lSCD6VdvLmCytZbm7lSG3iUs8jnCqB3JrzzQNB1i38QWkktrfRx2+rajcs08sDW3kTSzspjVWLhyHjOSBjLg9cHqPEFpe+IPA19a/ZfseoXlmy/Z5ZFby5Cv3WZcjrxkZoA3PtMH2v7L5qfadnm+Xn5tucbsemeKZcXtvb3NrbzShJrpikKkH5yFLEfkpP4Vw2v6XrGvXV1eR6Zc2IMFtbLFLPEJJALpZJCDG5AUIPXJyePWtd+GbqG8gU6Eb7SbfV5547KJodoge12jCu6rjzGb5ffOKAPSqr2N7b38DTWkoljWWSEsARh43ZHHPoysPwry648NeJCukLJZvJdWSWfk3UDwM0YWbdKkksh8zATj5B8w6k5IqLxF4Y8Qz6Ne2ttpjtPu1Oeymt2t/Njnlu5pIiXkb5FKtGQU+YEkErigD16ivP7vw3qj6zPqFrF5V62ru8d0ZASlqbQp6/d8znZ6jOO9Z0vhvUJND06CDQri1eGSJtTj823lOoERyKW+ZysmHZWPmbSwweqgUAek6he2+n2kl1eSCKBMbnIJxkgDp7kVYryfUPCuqy6ebeTTLzUP9FgjsnupoC9kyTuz7vnwCUKAFN2Qu09OfWKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKxfGuqz6H4R1fUrJIpL63tXa0ikBImuCMRRYBBYvIUUKDklgByRWf4Fkuku/E+n3V9c3qadqawQy3LBpCrWltM2SABzJLI2AAFDbVCqqqADVvfEOl2evWGjXF1jUr7PkwrGzdFdxuYAhMrFKV3EbvLfbnacateVah/p2h6prUn+tvfFthbKrfM0MVrqkFssYbupeKWULwFM7jk5ZvVaACiiigAoorF1rxVomh6zo+latqEVpfaw7x2McgYCZ125XdjaD8ygAkZJAGTxQBtUVwvxp8ep8OfAV3rSxRT3zuttZQy7tkkzZI3FR0Cq7kZGduMgkGsr9nfx7qPxD8BT6prMUSX0GoT2ztFwjD5ZF2rj5QqyqgBLE7Mkkk0Aen0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZ82s6dBrMGky3cS6jOhkjhJ5I+Yj2BISQgHlhHIQCEfABoUVi+J9Vn09dOtLBIjqOqXX2O1eYExRP5UkrO4BBYBInIUEbm2rlAS6w+A9QutS8MwPqEvn3ttNcWE9xtC/aJLed4Gl2gYXeYi+0cLuxk4yQDoKKqatqFrpGlXupahL5NlZwvcTybS2yNFLMcAEnAB4AJqa0uYLy0hurOaKe2mRZIpYnDJIhGQykcEEEEEUAS0V5/pPiTWL7UfCesSTWy6B4i3RWmnpARNCHt3uY5pZix3NsgIMaqoUzEbpNgZvQKACiiigAooooAKKKz9N1nTtTu722sLuKeezfy50U/dOSPxG5XTIyN0brncjAAGhRXn/AMTfEmsWOleJYPDU1tZ3ukaM2qz3VzAZuGWYRpEm4DdmCQl2yFwo2PuOz0CgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4l/8i5Z/9hrSf/Tjb0eDf+Rj8d/9hqP/ANN1nR8Tfl8LxzNxFb6nptzM5+7FFHfQPJIx7KqKzMx4AUk8CsltX/4ReX4m380HnXFpt1yO337fNgFjHGp3YIXdJaTr6jbnGCuQDKsP3vwY8BqPnvb6bRLkgcyXEpuYLieT1ZiFmlduTgOx6E16rXAaRpH2PV/BnhhZ/tMXhbTFup51Ty2MvlG0t8gk/K6G8YqMkGNMkDAfv6ACiiigAr4m8d+Jn8TftZ6SwaU22m67ZaZAkiKpQRXChx8vUGUysCTnDDp0H2zXiz+HtFttKvL46RpyeJbTxlCJ70WyfaFE+rRSxjzQMndb3EXQ8B9pwQQAatfU4T9uW5nW18G2qzSi2ke7keIOdjOohCsR0JAdwD23H1NdL+xT/wAks1X/ALDUv/oiCvRdW0TSvFPxJmtfEGmWOo22j6TFJbRXUCTIXuppRIzK4IyBZxhSMY3yZzkYl+Dmm2Nj8PtNudNs7ayi1bfq5gt4lRY/tLGVY+AN3lo6RBsDIjHAGAAR2tFFFABRRRQAUUVzXxNuZ7P4beLLqzmlguYNJu5IpYnKvG6wuQykcgggEEUAReCvH/h3xrf63a+HL37Y2kTLDPIqny33AkPG3RlJV1yO6Ej5SrNifHL4lwfDPwiL5IYrrVrtzBY2zuAC+MmRxkMY14zt7sq5XduHzr+xPczr8SdZtVmlFtJpLyPEGOxnWaIKxHQkB3APbcfU1lftharBqPxgNrAkqyabp8FpMXAAZyWmyuDyNsyjnHIPsSAfTXwA+IV98SfA82rarZ21re297JZyC2LeXJhUcMFYkrxIBjJ5UnPOBL4x+LegeGfHugeEWEt7q2pXUdvMluQfsYk4jaTPcsyfL1Ckt/dD4v7KWg/2J8G9NmeO5in1SaW/lScbcZOxCowDtaOONhnOd2QcEV8y3NzPdftViS6mlmkXxgkYaRixCJeBVXJ7BVCgdgAO1AH2/wCNfEEHhXwjq+u3XlNHYWsk4jklEQlcD5I9xzgs2FHB5YcHpXgv7NHxc8V+PPH2tab4jubaeyNk97DHHbrH9nZZUUIhHJXEn8ZY/KvPXPVfteav/ZvwaubXyPN/tS9gs92/b5WCZt2Mc/6nbjj72c8YPlX7Eug3z+Ktd8Q+Xt02Gy+wb2DDfK7o+FOMHasfzc5G9OOaAPr+iiigAooooAKKKKACiiigAryqw/0jWtC1N+J7/wAZ6j5qj7o+z2d7ZptHXmO1jJyT8xYjAIA9VryrRv8AmUP+xz1v/wBytAHV3v8Ap3xN0uFf3sWmaZcXM6N92GWeSNLeQA9WKRXihhkqC4OA43Hw0/5Fy8/7DWrf+nG4o03/AJKn4h/7Aumf+j7+j4W/vfAmmX/T+1fN1fZ/zy+1yvc+Xnvs87bu4ztzgZwAA8d/6Rc+FtMfi3v9Zh81h94fZ45bxNvbmS1jByD8pYDBII5qG5nsvgdqNjp80sN3aJd+HtMkjcpI0sdxJZWh3jG2RmWLL/KoYlvlHTpda/0f4j+F7qb5beayv9PjbrmdzbzKmOvMdrO2enyYzkqDylr8/wAFvCN03M9/e6LqFy3/AD0nuNQt5pnx0G6SR2wMAZwAAAKAOl1+2gj8SeBNL02GKJbK6mvBbxIESK1is5YCVHAAV7mBQo5+fgYUkdhXK/8AH78U/wC5/ZGi/Xzftk//AI7s+we+7ze235uqoAKKKKACiiigDF8b6rPoPgvX9Xs0ie50/T7i7iWUEoXjjZgGAIOMgZwRXP8AgzSoNB8aX+kWbyvbaf4c0i0iaUguyRyXygsQAM4HOAK0Pix/ySzxl/2Bb3/0Q9eP/sm+Mdd8b6r4x1LxPffbr2KGwt0k8mOLEYa5YDCKB1ZucZ5oA9Q0yfTvs/j/AFzXFjm0RrqWJ5Z4/NDWltbpFNGUwWMazJd/JjBLOwBD5boPBEGo2vgvQLfXDK2rQ6fbx3hlk8xzMI1D7nydx3ZycnPXJr5V1D4qeI5/GOu/C61h0iLSdV12/wBJN3JbySTxpdXcqu/EiqSvmkgYHQZr7EoAKKKKACiiuf8AH/ie18GeDdW8Q3y74rGEuseSPNkJCxpkA43OVXOCBnJ4FAHQVFd3MFnaTXV5NFBbQo0kssrhUjQDJZieAAASSa8v/Zw8d6x8QvA99qviD7N9rh1Oa3X7PGUXy9qSKMZP3fMKg9cKM5OSfBf2tviDrV3431DwbBcyW2hWaW/nW6FcXMpQS72IUNgeYo2ElcxhuuMAH2fRXC/AzxBP4n+EvhnVLzzTcva+RK8spleV4maIyMx5JYxljn+91PU91QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBn+IdKg17QNT0i7eVLbULWW0laIgOqSIVJUkEZwTjINeNeINem1aw1W6ubK5W4sdGitvGtpbpGpVFIleGNZZQ/3Gu1V1wjJOzpK7xIjey+IdVg0HQNT1e7SV7bT7WW7lWIAuyRoWIUEgZwDjJFeQahpUsV9b3U8FjNfWGraWNbug9x/pl9cXcL+UNkke6O2WWFojMsoCuiDBR8gHpXgO2nOnXur3sMttd65dHUXtpFKNAhjSOJGU8rIIYot4ycSb8HGAOlrlfBv/Eov9Q8KLza6TDbS6eepSykDpHG7d2R4JlBx9wREszlzXVUAFFFFABXlXi//QtY8T26/wDHp9t0DXrmV/8All/pixTMT0WJIbBHJP3f3hJxgL6rXmHxZs31PX9HgskvroQ2s6aza2u079KneJJkPyO/mMUVkVNrusE6owcLQBD4x/4mPjLXtEh5TX7LT9BkmHKxZF/Pcru/hlFsSyjBw0kJYbWzXqteNfDODTrTxiPEGmmKXw74leePRZFk3vFIsMPneYclnkuPsjykyHcn2f5yJJXUey0AFFFFABRRRQAVi+N9Kn17wXr+kWbxJc6hp9xaRNKSEDyRsoLEAnGSM4BraooA+K/2Kf8Akqeq/wDYFl/9HwVifG/Sp/GX7SuraRoDxXVze3VtaIyEuiOsEayFygJAQq2/g7djZ6Grf7QzadYfG+S4+HGpX3/CQTvsu49MXZ5N2w8spE8ZDNI+TvUAnczAsSzKvYfsb6l4el8R65Nql7cv45vt/lvdSkrcQEh5NhJ+aUupZt2TgAr0koA+qdJ0+10jSrLTdPi8mys4Ut4I9xbZGihVGSSTgAckk18bftIf8Ub+0dp/iT/j93/YdX+z/wCrx5TCPy93PX7Pndjjd0OOftSvmX9tjUNA/sbQdPuopZvEe+Sa1aKcKLeE7RIZE5JDlQF4HKMdw2lWAM/9sjxD/bP/AAhvhvQbr7f9tzqAt7WPzfP34jtnRgDu3ZmACk5yMj7te4fBHwe/gb4aaPo91HEmo7DcXpRFUmaQ7mVipIYoCI92TkIMYGAPjr4Xta/C74raVP8AE3w9cwx+Sk8P2iM7rRnwY7ny/wCPbhgV6qcnG9Ntff8AQAUUUUAFFFYniHUru1vNLsdO+zpc38roJrhWZECRs5+UEFmOOBkcZPbBANuiuN8NeJ9S17VbeGK0tIbQafb3tw7SMXzK86bYxjBXMOQxxwenPHZUAFFFFABXlV//AMSq21aJf3T6B4mg1K3lk4aO1u5Ee6uHzx5QW61CPeRtVY2Od0ZYeq15h8TSD4u0yKO6ltLG40+4g8QXEVtFMsFkxXypJvMDKB5gdBvjdRHJdNlAjsACHUv+JxH4ms1+dPFWsnQbe6bqlrFa7bpQTyuxodQCAgr5rbsFXLH1WvKvh19ntPElusn9pSaW8M9p4YuLjyRbxWSGINAjLhpGfyPNjZ9++CNGDZ82vVaAOV+IX+j22hamnM9hrNn5Sn7p+0SCzfcOvEd1IRgj5gpOQCDykHHgjSvD0fF3a+JotPtbU8NHBa3/AJ8aNnpiygEgLHLqFOWLjd2vxB+wt4H16HVftJsriyltpEtNvny+YpQRxBuDKxYKi92ZR3ryBtL1TXdXuDfr9t8XNNJY+J9J0yVYbaPTjEciJnXhrlFssM7+Y2zYrxLE/lAHqvw4/wBN0SbxCeG8RTDVQg6JE0UaQKR2byI4d4yRvL4O3FdVVTSdQtdX0qy1LT5fOsryFLiCTaV3xuoZTggEZBHBANW6ACiiigAooooAz/EOlQa9oGp6RdvKltqFrLaStEQHVJEKkqSCM4JxkGvkb9jfULrR/ibrmgX8v2L7TZOJLO4URyPcwyDC4Ybtyq02VHYEkfLx9k1+ff7Qn9naV8afEp8L3kqrI7fajC+As0seLiMOHJYEs4YHbgs6bcLyAdr+yD4dn8R/EvUfFWoXcssmkIZGZ5S0k1xcB13OSDuG3zSTkHcV6819n14h+yJqGgXPwuNpocUtvfW10x1KOacSO8zKuJQBjbGyqAowPuMPmILN7fQAUUUUAFeIfthwajN8Hy+nmUW0OoQSXwSTaDDhlG4ZG4ea0XHPODjjI9vrlfir4e/4Sr4ceItGW1+1z3NlJ9mh8zy906jfD82QBiRUPJxxzxmgDyr9in/klmq/9hqX/wBEQV86/EGx1jx38f8AXtLtz9o1K71qWxiYphUjjcxqW2KSFSNAWbBOFJOeTXVfs2fFbS/h3pXi231ye5bzoVutPtvmMMk6K4MeQG8tpMxjftxhOTwAer/Y6+HMk1+/jzUl2wQeZa6dGyurPIQFeYHgFQpeMfeBJfoUGQD6k8PaVBoOgaZpFo8r22n2sVpE0pBdkjQKCxAAzgDOAK0KKKACiiigAooooAKKKKACiiigAooooAKKKKAOV8f/AOk/8I5pX3f7Q1m2/e9fL+z7r3p33fZdnUY37ucYPKXP+keFNS1N+J7/AMZ2vmqPuj7PqtvZptHXmO1jJyT8xYjAIA6vWv8ASPiP4XtZvmt4bK/1CNemJ0NvCr568R3U646fPnGQpHKL/wAkPt9cbiJpo/Fk0Q5ZIjejUZIVP8TKm5FJ2hiATtB4AOr1L/kqfh7/ALAup/8Ao+wrqq5XxN+78a+DpbXm9ea6gmC/M32I27PISvZfPjs8vjglFyN+G6qgAooooAK8lltoPEupwx6hDFeW2t+I7iO7sZUEuLLT0miRWJ58kXUEUpHChrnYc7zv9P1bULXSNKvdS1CXybKzhe4nk2ltkaKWY4AJOADwATXAeCtPutN1XwDpt5FsvdK8JS297GrB/s8jNZKoYqSBuMEwU5w3lvjO04AKmuf6Pp/xI1dOLjRNah1eIjhj9n0+ykeNW6p5kayRFhn5ZWyGBKn1WuV8G/8AIx+O/wDsNR/+m6zo+E//ACSzwb/2BbL/ANEJQB1VFFFABRRRQAVx/wAXvEz+D/hp4h1uBpUube1K27xorlJpCI4mw3BAd1JzngHg9D2FeFftk6hdWXwjhgtpdkV9qcNvcLtB3xhJJAORx88aHIweMdCRQBwH7FPhCO4v9a8W3ltu+y4sbGRtjKJGG6YgfeVgpjAYYGJHHPOPFfiFqF1pHxo8S6lp8vk3tn4gubiCTaG2SJcsynBBBwQOCCK+n/2Kf+SWar/2Gpf/AERBXy18Yrae1+K/jCO6hlhkbVrqQLIpUlHlZkbB7FWBB7gg96AP0ftLmC8tIbqzmintpkWSKWJwySIRkMpHBBBBBFfEvhHXv+Fr/tS6Rqd/Jcx2RvTNZRA4aKK2R5YUwSwXJjBcKcEu5GM5r6g1ayvvCvwCvLH7T5epaT4ZeH7RayMNssVqRvRuCPmXIPB6dK+X/wBjbT7W9+Lk09zFvlsdMmuLdtxGyQvHGTwefkkcYORznqAaALf7a3/JU9K/7AsX/o+evev2WdZTV/gtoyfa5bm5095rKcyFiYyrlkTLdQInixjIAwO2B4/+2x4Z1Ea/o3ikLE2ktapphYP86TB5ZACvoVY4Iz905xxnu/2Kf+SWar/2Gpf/AERBQB7/AEUUUAFVdR06y1O2+z6lZ295BkN5dxEsi5HQ4IIq1RQBBBZ20Epkgt4YpDGkJZECnYmdq5H8I3NgdBuOOtT0UUAFFFFABXlT/wDE98TCSX9/aazrM2nz238TabYwToySqP8All9t3Enncs8aOcP5Y9K1bULXSNKvdS1CXybKzhe4nk2ltkaKWY4AJOADwATXAeENPutK1vwBZ6lF5WpR+Gb43oLBma5MuntMzMCQzNIXZmydxJOTnNAFTVf9BtfGuqQ/IvhrxBHqsSr0jiFlbSXaxp93dJHNd8HALzFiQx3j1WvNZ9Putf8ABPxPbS4vNl1ua/t7OEsFYyRWy2RDEnaMy27kHONrKTg5A7/SdQtdX0qy1LT5fOsryFLiCTaV3xuoZTggEZBHBANAHNfEK5gMnh+wu5oobSXUFvbyRnCmC3tFa584k8LGJordGY8AS4yCykYGl208L/D/AFi+hltte1vUGuNU3IY3DyaZMzwbeCsam3t12H/nghbc4LGH4of6T/wsPzvm/s/wY/2bt5f2j7V53Tru+ywdc42cYy2er8Zf8jH4E/7DUn/puvKADwB/o3/CR6V97+z9Zuf3vTzPtG296dtv2rZ1Odm7jOB1VcrpP7v4m+JYY/kifTNOuXReFaVpLtGkI7sUiiUt1IjQdFGOqoAKKKKACiiigDP8Q6rBoOganq92kr22n2st3KsQBdkjQsQoJAzgHGSK+Vf2W/CmnfEG68da3430iLVpLt1jF1cQ4QySmR5/LxhVk/1ZyuGTcMFd3PsH7U2sppHwW1lPtcttc6g8NlAYywMhZwzplegMSS5zgEZHfB5r9in/AJJZqv8A2Gpf/REFAHkv7HHiZ9K+Jc+iO0pttatWQIiKR50QMiMxPIAQTDjqWGR3H2zX5t/B25ntfiv4PktZpYZG1a1jLRsVJR5VV1yOxViCO4JHev0koAKKKKACsrxXr1j4X8OajreqybLKxhaaTBUM2Bwi7iAWY4VRkZJA71q181/tta9fWXhzw7oltJ5dlqU001ztLBn8ny9iHBwVzJuIIPKIRjFAHjWk+CNa+KuneOfiJqM9jptpZpcXbi3t1AnuEj80xKgI2jbjMjEklgfnJYjv/wBkT4kaq/ig+D9b1SW506e1ZtPjuN8jxSxqv7qNudsflK52n5RsG3BJDd38I9N839kW9h02z33t9pmqZS3izJcSlpkXgDLMQqKOpwAOwr5V+FXiH/hFfiP4d1lrr7JBbXsf2mby/M2wMdk3y4JOY2ccDPPHOKAP0pooooAKKKKACiiigAooooAKKKKACiiigAooooA5XxL/AKB4y8L6u/MD/aNIlJ+VYvtAjkSRm6cyWscQU43NOuDkBWh+GVtBefCHwna3kMU9tNoVpHLFKgZJEa3QFWB4IIJBBrq7u2gvLSa1vIYp7aZGjlilQMkiEYKsDwQQSCDUtAHAeCNP1geJETXYrl/+Ec0xNJg1GRiRqUkpR5pssdx+WG1PortMu6TaGHf0UUAFFFFAHK/Fj/klnjL/ALAt7/6IejTf+Sp+If8AsC6Z/wCj7+uqrj/A3hOfw1dz+bcxTW0On2ek2YVSHNvbGYo8nbzCJ9pA4Pl7xt37EAMrUNVn8MT/ABJktkil1TZDq9lGwLJK8tsttBDgEM0jTWbLsXrvQAlmIHa+HtKg0HQNM0i0eV7bT7WK0iaUguyRoFBYgAZwBnAFRa34e0vXJrGbU7XzZbGZLiB1kaNlZXVwCVI3LvjjYocqSiEglRjVoAKKKKACiiigArhfjT4CT4jeArvRVligvkdbmyml3bI5lyBuCnoVZ0Jwcbs4JAFd1RQBxXwc8Ff8K/8Ah9pugyvbTXse+W7nt49iyyuxJOerbRtQMeSEHA6DP8bfB3wn4x8Xad4j1S1lTUbR0eUQ7PLvQhBVZ0ZWDjC7eMEqcEkBcei0UARXdtBeWk1reQxT20yNHLFKgZJEIwVYHgggkEGvNfgn8KIPhhJ4kEF/LeR6jdIYC+Mrbop2BwAP3gaSQEg4ICkBckV6fRQBn+ING07xDo13pOtWkV5p10nlzQSDhh1HI5BBAIIwQQCCCBUXhbw9pfhXQrXRtBtfsmm227yofMaTbuYu3zMSTlmJ5PetWigAooooAKKKKACiiigAooooA5X4sf8AJLPGX/YFvf8A0Q9Gm/8AJU/EP/YF0z/0ff10t3bQXlpNa3kMU9tMjRyxSoGSRCMFWB4IIJBBrj/Aehaxpeq3c2tSee0WmWOlLdPKZHvGt2uGNwc8jeJ0yGOQ4kHzKFdwCrHq/wDwiFn8QsweYmk+brlrZ78b4JYTKx34ON9zHedclfQLsFdV4T0j/hH/AAro2jef9o/s6yhs/O2bPM8tAm7bk4zjOMnHrVTxF4UsddvLO6mluba4gmt5Xa2ZV+0LDMs0ccoIIZRIoYHhlywVgHcN0FAHlXxH/wCap/8AYmQ/+5Kur8cfudR8IX8vy2lprK+e/XZ51vPbR8dTmWeJeOm7JwASM/xd4Z1G+8Rrd2CxywXr6Ws5Z9n2YWV611ux/GHV3TjlWCcFWZo+w1TT7XVbCWzv4vNt5MEgMVZWBDKysCCrKwDKykFSAQQQDQBz+k/vPib4lmj+eJNM062d15VZVku3aMnswSWJivUCRD0YZ6qsrw3osehWEkC3Vze3E0z3FxeXWwzTyMerlFUHC7UUAABERRworVoAKKKKACiiigDwD9tb/klmlf8AYai/9ET1tfsk6VBp3wW0+6geVpNSuri7mDkEK4cw4XA4G2FTznkn2A7D4x+Cv+FgfD7UtBie2hvZNktpPcR71ilRgQc9V3DchYcgOeD0MXwO8M6j4P8AhXoOia0sSahbpI8yRvvCGSV5NuRwSA4BxkZBwSMEgHxV8IfDOot8dfD2iTLFb6jp+rB7hJHyFNsxklXK5BOImAxwTjnHNfofXn+j/CzQ9K+K2qeOoBm9vYQi23koI4JTxLMhAzucAZPXLSklt+F9AoAKKKKACvlX9uf/AJkn/t+/9t6+qq5rxx4F8N+ObW2t/FWlR38ds5khJd43jJGDh0IbB4yM4OASOBgAi+E//JLPBv8A2BbL/wBEJXxLp/wu1HT/AI66X4J1exluoX1BCS58kXdirFnlUhuAYkc4DEggr94Yr7/tLaCztIbWzhigtoUWOKKJAqRoBgKoHAAAAAFS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFcz8QbjUINDgXSLw2d5Pe21uk20Nt3yqpyD1HPNc/pHi/UdR1C4t7fyori41FLFFuVLpZutp5kqEKQXIdHGMjPJzgYIB6NRXBWvjHVL0u1vZWSxW+nteXDPI+WZZJY8RgDlSYsgkjgjrniF/F2twpPLNFppS3tLLUZFRHy0VxI6eUCW+8vlsd/Q5A2jrQB6HRXmuveMdQKarFbAGxms9QFreRxmJklgQ5wS5L4IIzsUAgYLV6Hp7M9hbM5LM0Skk9zgUAT0UUUAFFcjqMN3/wn2m2iatqEdpc2V3dPCrJt3xyWyqBlc4xK+RnvVGPxVrFxYRyRw2Udxd3c1vZQxxtO8ixNIrlgWjVfuKeXAGTySQKAO8orzmLx1qVzYpfQWlpFBFpthqFxHIWdm8+WVGjUggDHlZDHPpjnIZrninVPs2sWt1jT7pFaW1jSJwzRJcInmLMCUcEOhIG0rvAIPWgD0mivP77xxeafaT6lPa28tiTfJFBGWWWM2xcEyMcjDeWc8DYSB81XNc1zWtKght/M0+61WWOS5SK3tmIaKMLuJ3SqFALqNxbnIwvagDtKK81TxrqqwatqvlwSWIg09ra1I+aJ7kIOX4yoZyTnsO1XT4j16YjTZbWCxv3S6lFzPGQrxRLCcrGshKsTMBgucbGbkYFAHe0VkeDp5brwjodxcSNLNLYwSO7HJZjGpJJ9Sa16ACiivO/GGv6npHifV5Y7pl0q00m3MkW1cRSTPdKs2cZ4aKJSOgDEnpQB6JRXB2HivUWihlZLd7aCexsZ1YN50z3CQnzVI4CqZhxg52PyMU6y8T63eWWiyi302BtXvntIDl5PKVYp3LsPlyf3I+UEdTz3oA7qivOoPG+oJbWcuoLZQi/s5ZYPKikkKTRzwwBSNw373nXAG3HQk9am0XxFqWp+INLt71GtZYbu7tbiNcKsuyJHUlQ7gffHG5ue/YAHf0UUUAFFFFABRRRQAUUUUAFFFeW+IvEur6VqXilzesLIX0NjafKv+jSfZ7aXAOOQ4kl5PQqoH3qAPUqK4efxffQu1yYLVrOS6vbKKEbhLG9ukzb3OcbW8k8YGA6cnNR3HifX0trD9xpcVxdaZdaoeZJEVIvIwn8JJPnEE8YwDg9CAd5RXAHxhqXnGzdbVb65htLiySKBpd3nidvKILqGZVtnO8sikdhjmfwf4gvNc1y1luVaBX06QyW4bKCVLhoywAJHO09z16nrQB3FFFFABRRXI+Td/8ACwPsv9rah9k+yfbPI3Jt3ebjb93O3HGM/jQB11Fedp4w1ubQdPu0t7Fb6/gkvILWKNpiYUC7izM8argumSTxuAAapYvGl/c+Tdw21rHY79NWSN9zSN9saNeGyANhkB6HOMcdaAO/orza68U6pcWzQXu2wvhf6cRbxxOjLDJfxxsBLkpKrKSCy46kEc1NJ46v7exhvZrW0eG+tpbi1jUsrW5WWKMCZjnj96CxAG3aRg9aAPQ6K4XxT4l1jQbSRVNjfahbW817NFBbMoaFAvJLSgR9SM5c9CFPIqrL4s1e1k8QTEQ3EKapbWNlF5fzRebb27jccjcMyscEgljjIGMAHolFeba34n16TRNStfIh0zUYNNu7uSaRTllj4Uxqr5QnIblm28fezmvQtPZnsLZnJZmiUknucCgCeiiigAormfiDcahBocC6ReGzvJ722t0m2htu+VVOQeo55rn9I8X6jqOoXFvb+VFcXGopYotypdLN1tPMlQhSC5Do4xkZ5OcDBAPRqK4K18Y6pel2t7KyWK309ry4Z5HyzLJLHiMAcqTFkEkcEdc8Qv4u1uFJ5ZotNKW9pZajIqI+WiuJHTygS33l8tjv6HIG0daAPQ6K8117xjqBTVYrYA2M1nqAtbyOMxMksCHOCXJfBBGdigEDBavQ9PZnsLZnJZmiUknucCgCeiiigAooooAKKKKACsO58V6JbtbFtRtXhnleHz0mQxxsqFyHbOF4U/jirniHT31bQNT06Odrd7y1lt1mXrGXQqGH0zmsKPQ9QutQ0K4vbLSbVdNlLMltI0gZfIeNduY1xgsMDsM89qAOguJtPuBAlxJaShmSWFXZWyc5Rlz3yMgj04rPkTwxe2F5NIujXFlNLvuXYRPG8igDLnoWAUdeQBXMWfw/lOmNbXz2fnf2AukxXEYLPBJ+8y6EqMDDrjGD8vTpVo+FNQvNSjvryLTLYieyLW1u7PFst/NO4ZRfmPmAAYwAi80AdHZyaDcSGGyfS5Xa0UbIjGxNtzt4H/LP5jjtz71E9x4aOnSXrzaObBlS2ectF5RVCSkZbphSzYXsScda5i88B3dzpbWiT2kDPLqzPIgJ+W6kkaMYwM4VkDDjpgE8Gn6h4U1W9nn1A29jb6g8sbQx2188awbInj8wP5JDMQ5UqyY2gelAHRmw8M/2mym00b+0b1Gcjy4vNnRgQx6ZYEE565zVptc0e3WRW1PT4lg2q4NwgEeeFB54z2rlbfwlqyyLHczafOst1Y3s94uY5Ukt0iDJHGFwEYxH+IYErjHq218EXMVtYxv9hLQaXqNm5GeZLiSJkYfL0wjgnr83Q5NAHbPf2aX6WL3dut6670tzIBIy+oXOSODzVmvPdN8FX1pq0c1yYbuEz210zm9ljMTxxJGcRhCJPuZBLLw2COOfQqAMvU9R0mxu/Mu5bQahDbSOiFl8/wArhnCA/Ng+WCccEqPSqVs3hnW9HjIi0q4sUkEnlSLGywytk8ryFc7znvkn1qjc6BqP2rxAkMOnT22quZhcTSsssLeQsQXaEIYArwdwwGPHHOdceBp5niR1sHtBb6TDJCwJVvss0ry/LtwQVdQPXBzigDp7eLw80gsbePSTJLbxgW6LHl4FJZPlHVAWYjsNxx1qqo8IwPeOv9gxvM6rdMPJBdmO5Q/qSckZ6nms6Lwtdxa2piWxTTk1Iaik6sROuIfLEQTbjHbdu+58uO9Z8XgS6TRILMmw86PQbnSy3ODNIVw33fu8Nk9eehoA66G30JNbulhh0xdXmjzcBFjE7occv/ER068VmpaeCm0t3S38OnTraXczBIPKikwBknorYwPWsuDwjqAuIoZxYyWkV5NfG4MjedKZIXjMTDbwvz43bs7VAx3EGneE9cs/sc26xlWwuUktbGa5aRFQQSRbTP5IbjzAVyrY2kZ+b5QDqJoPDkEkHnRaRHJNAtpDvWMGSJuFiXPVTzhRxVUWvg9NFLiDQF0iGYsWCQiBJfuk/wB0N29e1c8/gK8bStRtvMsmkudK+xR5ztjkM0shA+XiMeYoHf5RxVjWPBt/PrU+oWUsAQXy3MVuJ3gDL9lWE5dVO1gQcYDZHHGeADubVIYrWGO0WNLdECxrEAECgcBQOMY6YqpqOs6fp7SR3N3AtwsLTi38xfNZFBJKrnJ6Gm+G9P8A7K0KzsREkIgTYI0laUIM9A7AFsepA+grCudA1H7V4gSGHTp7bVXMwuJpWWWFvIWILtCEMAV4O4YDHjjkA3dN1vTdRshd2t7btF8of96uY2IBCtg8Nz0prvot9dTWztp1xc3lsqyxEo7zwfNgMOrJ87Yzx8x9TXJ3HgaeZ4kdbB7QW+kwyQsCVb7LNK8vy7cEFXUD1wc4q5F4Wu4tbUxLYppyakNRSdWInXEPliIJtxjtu3fc+XHegDUaXwqt4l20mhrdWoSFJiYg8OQdiBuq5GcD64q8g0iO8ttPjFgt1bZngtl2B4shlLqvVchmGR2Y+prjYvAl0miQWZNh50eg3OllucGaQrhvu/d4bJ689DU58I6g900UosZLRr37e1w0j+czeR5RiI2/d7bt2dnGO9AG67+FZ9NkldtEk0+3V7Z3JiMUauyl4yegDFVJXuQM9BU0EXh3SmtVgTSbJncG3CCOMszgLlMYyWCgcdQMdq5bTvCeuWf2ObdYyrYXKSWtjNctIioIJItpn8kNx5gK5VsbSM/N8rH8BXjaVqNt5lk0lzpX2KPOdschmlkIHy8RjzFA7/KOKAO3/trSxYPenUrL7EjbGuPPXy1bOMFs4B9qkfU7BLuC1e9tVubhd8MRlUPIvqozkj6VxmseDb+fWp9QspYAgvluYrcTvAGX7KsJy6qdrAg4wGyOOM8JpvhDUNO1LTZNOS1sbePyRcgXjziRI92E2PFyRuwHDIRnOOMEA7+iiigAooooAKydV8RaXpkd0Z7uJ5rVVaa3jdWlQMQASucgfMOta1cHceFdTl0LUtHMOlvDPcTTx3byN5j+ZP5hDpswODtJDHO0cDPAB18WradLaC6i1C0e2JIEqzKUJHUZzjjBqtIuhXj6hayDTJ2DrPeQsI2O9Qu15F9QETBPTaPQVgS+DnuPEb3l3HYzWB1Y34hkXdhPsMcA+Urjd5iFvpg5zxVGTwZqctncWZawRI7XUIILhZG8y4a5JI80bPlA6tgtuYA8dKAOlRvC8t+9xG2ive3TNavIpiMkzYG6MnqxxjK/SrW/RJJpYt2mtLZQNDImUJghbBZSP4UOxcjgHaPSubvfB1xLJftb/Y4zNHpqxnkbfs829+i8ZGMY7jnFVJPBV7NB9kuodPmtbdLtY2Fw8cl358gfEhCfJjGSQWywBwMYoA6O5/4RW70+Oe6/sOexn8u3SSTymjk2FtiAng7SzYHYk46mrMbaDpNykER0uyuFRlWNTHEwQfvGAHBxyWP1zXKx+FtfULcXD6dqFyYru2MV3KdqRzGPB8xYh5jDyyDlFyGAz8uWkj8EXEcckbS21xm90+cSy5LvHbpErbuPvHYxA6fN1GTQB17axpiWtvcvqNmtvcMFhlM6hJSegU5wT9KkXULJtQawW8tzfKu9rcSr5gX1K5zjnrXA3vgXUHupZg1vcxSvfI1qbyS2Xy55vMHzqjckcMu3B4OeOdXRPDWo6b4kS5hNvb6blnmiW4aczOY1UMFeMGNuBkhzkDpzwAdmeBzXOzeJfDsWo20pvbBnnjlQXiyRlFWMpuRpM8cuvFX/ABPpr6z4c1PTYphC93bSQLIRkKWUjJHcc8j0rCk0DUNQ1SyvL6y0q1Fva3NuY4JWlyZFjVTkxr0CsMY4GOucAA2LzT/D80VtZXlppUkcA3QQSxxkRjB5RSOOAenYGmRv4bXTRcxto40/dHiVTH5WYfmTnplNmR/d28YxXLx+AppNNvI7o2LXkmj2mnxTlS5V4kcOCSAdjbgDjkjOQKuw+F7+fXbPVL1LCApqi30ttDI0iKq2csClWKLucs6nkDAUc5HIBsWFr4YVrmPT4NFB/d3U6wJF2PmRyOB6H5lY9+RTVbwtb2s+oqdEit9QJjlugYlS5JzlWfo/fgk965hvAV7/AGbpttHLZRm2sbqBwM7ZHe5t5kBG3lCIWVu/zcA5NP1LwjrF013fwJY22q3E8kqGG8ZUtt0McXBMJEu7y8sGQdgDwSQDo20bwo80WltpuhtLGrSR2hgiLKrY3MExwDgZOOcCiWTwpNJO8r6HI8wS1mZjETIGGUjb1BA4U+nFZVr4X1GPVomlexe2XURqTXakrOWEPlmMJtwB2zv+58uO9Za+AL1fCg01W08XY8Lf2KHBbaLjZjfnbnZu5zjPfFAHVvpXhZ5E0h7DRWeFWmSyMMRMYb7zCPHAPc45rU02+sb+336ZdW1zAh8vdbyK6qR/DxwO3FcTN4JuX1a+eeO3vrSe5nukaW+miKmSJkKmJUIOAxTduHykcZHO94K0nUtJt7qPU5o2RnX7PGsvnGJFQLtMnloW5HGQSB3PYA6OsO58V6JbtbFtRtXhnleHz0mQxxsqFyHbOF4U/jirniHT31bQNT06Odrd7y1lt1mXrGXQqGH0zmsKPQ9QutQ0K4vbLSbVdNlLMltI0gZfIeNduY1xgsMDsM89qAOguJtPuBAlxJaShmSWFXZWyc5Rlz3yMgj04rPkTwxe2F5NIujXFlNLvuXYRPG8igDLnoWAUdeQBXMWfw/lOmNbXz2fnf2AukxXEYLPBJ+8y6EqMDDrjGD8vTpVo+FNQvNSjvryLTLYieyLW1u7PFst/NO4ZRfmPmAAYwAi80AdHZyaDcSGGyfS5Xa0UbIjGxNtzt4H/LP5jjtz71E9x4aOnSXrzaObBlS2ectF5RVCSkZbphSzYXsScda5i88B3dzpbWiT2kDPLqzPIgJ+W6kkaMYwM4VkDDjpgE8Gn6h4U1W9nn1A29jb6g8sbQx2188awbInj8wP5JDMQ5UqyY2gelAHRmw8M/2mym00b+0b1Gcjy4vNnRgQx6ZYEE565zVptc0e3WRW1PT4lg2q4NwgEeeFB54z2rlbfwlqyyLHczafOst1Y3s94uY5Ukt0iDJHGFwEYxH+IYErjHq218EXMVtYxv8AYS0Gl6jZuRnmS4kiZGHy9MI4J6/N0OTQB2z39ml+li93breuu9LcyASMvqFzkjg81Zrz3TfBV9aatHNcmG7hM9tdM5vZYzE8cSRnEYQiT7mQSy8Ngjjn0KgAooooAKKKKACiiigAooooAwfGM8NvpavNd3sLl9kENk4WW4lIO2NeDk9/TgluAa0NDS+j0XT01eRJdSW3jF08YwrS7RvI9i2aNU0jTdWWJdU0+zvRES0YuYVk2EjBI3A44q1bQQ2sEcFtFHDBGoVI41CqoHQADgCgCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZOsjQSLC4jlKkI5XcFOODjv9K4zTdSM3w9sb7XdTu1lLEPLa4SW4feyqihRnLHGFXknHvXZzwx3EEkNxGksMilHjdQyspGCCD1BHasv/AIRjQPsC2X9h6X9iWXz1t/skfliTG3eFxjdgkZ64oAk8MLqKeHtPXW23al5K+ecgnd6ErgE+pHGc4rTqGztbeytkt7KCK3t4xhIokCKvfgDgVNQAUUUUAFFFFABRRRQAUUUUAFFFFABXKaZJcTeNLgaffXV1p0Ecq3plYNEs5ZDHHHwOUXeGx0yu7Lcjq6zbPQdIsbxruy0qwt7pyxaaG3RHJY5YlgM8k5PrQBpUUUUAFFFFABRRRQAUUUUAQXxUWVwZLg2qCNt04YKYhjlsnIGOvPHFYXgeS6ntb6eSa5m02W43ac10cymHYo3HIBwXDsuecEeoA3ry1t721ltryCK4tpVKSRSoHR1PUEHgj2qHTdL0/S43TTLG1s0c7mW3hWMMfUhQM0AXKKKKACiiigAooooAKKKKAOds7q+Hj3UrKa68yxFhBPDCIwvls0kitz1Odoqt4PluJ9U1KW2vrq+0QJHFDPcsG82dWfzWjIA+TlBkfLlTtAA52xomlf2k+o/2ZY/2g42vc/Z081hjGC+MkY460mlaHpOkFjpOl2NiWUKTbW6RZA6D5QOKANGiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26113=[""].join("\n");
var outline_f25_32_26113=null;
var title_f25_32_26114="Ultrasound of fourth extensor compartment wrist";
var content_f25_32_26114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the fourth extensor compartment of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The extensor digitorum and the extensor indicis of the fourth extensor compartment (IV) are shown in this ultrasound image, along with the ECRL, ECRB, and EPL. The image was obtained with an ultrasound probe placed at the site of the red mark in the photograph.",
"    <div class=\"footnotes\">",
"     ECRL: extensor carpi radialis longus tendon; ECRB: extensor carpi radialis brevis; EPL: extensor pollicis longus; LT: Listers tubercle; IV:&nbsp;fourth extensor compartment (extensor digitorum; extensor indicis).",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26114=[""].join("\n");
var outline_f25_32_26114=null;
var title_f25_32_26115="Dimercaprol: Pediatric drug information";
var content_f25_32_26115=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dimercaprol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/42/9893?source=see_link\">",
"    see \"Dimercaprol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35635?source=see_link\">",
"    see \"Dimercaprol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BAL in Oil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Arsenic Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Gold Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Lead Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Mercury Toxicity",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Chelating Agent, Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/42/9893?source=see_link\">",
"      see \"Dimercaprol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild arsenic and gold poisoning: 2.5 mg/kg/dose every 6 hours for 2 days, then every 12 hours on the third day, and once daily thereafter for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe arsenic and gold poisoning: 3 mg/kg/dose every 4 hours for 2 days then every 6 hours on the third day, then every 12 hours thereafter for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mercury poisoning: 5 mg/kg initially followed by 2.5 mg/kg/dose 1-2 times/day for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lead poisoning: (use with edetate calcium disodium):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild: 4 mg/kg/dose for one dose then 3 mg/kg/dose every 4 hours for 2-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe and acute encephalopathy: (",
"     <b>",
"      blood lead levels &gt;70 mcg/dL",
"     </b>",
"     ): 4 mg/kg/dose every 4 hours in combination with edetate calcium disodium for at least 72 hours; may use for up to 5 days; if additional days of therapy (&gt;5 days) are indicated, a minimum of 2 days without treatment should elapse before considering another treatment course",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BAL in Oil&reg;: 100 mg/mL (3 mL) [contains benzyl benzoate, peanut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer undiluted, deep I.M.; when used with calcium EDTA for lead poisoning, do not administer calcium EDTA with first dimercaprol dose; begin with second dimercaprol dose",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not mix in the same syringe with edetate calcium disodium",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote to gold, arsenic (except arsine), and mercury poisoning (except nonalkyl mercury); adjunct to edetate calcium disodium in lead poisoning",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F160844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension (dose related), tachycardia (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, fever, headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, burning sensation (lips, mouth, throat), nausea, salivation, throat irritation/pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Burning sensation (penis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia (polymorphonuclear)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesias (hand), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharospasm, conjunctivitis, lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinorrhea, throat constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dimercaprol, peanuts (injection in peanut oil), or any component; hepatic insufficiency; do not use in iron, cadmium, or selenium poisoning (produces complexes more toxic to the kidney than the metal alone); do not use iron supplements during therapy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment or hypertension; produces hemolysis in persons with G-6-PD deficiency, especially in the presence of infection or other stressful situations; due to increased frequency of histamine-release related side effects, pretreatment with antihistamines is recommended; urine should be kept alkaline to prevent dissociation of chelate; fevers may occur in up to 30% of children and may persist for the duration of therapy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Dimercaprol may enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Dimercaprol may enhance the adverse/toxic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Dimercaprol may enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5026033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension.  Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific heavy metal levels, urine pH, renal function, infusion-related reactions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfhydryl group combines with ions of various heavy metals (arsenic, gold, mercury, lead) to form relatively stable, nontoxic, soluble chelates which are excreted in the urine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To all tissues including the brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid to inactive products",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and feces via bile",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gracia RC and Snodgrass WR, \"Lead Toxicity and Chelation Therapy,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2007, 64(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26115/abstract-text/17189579/pubmed\" id=\"17189579\" target=\"_blank\">",
"        17189579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment Guidelines for Lead Exposure in Children. American Academy of Pediatrics Committee on Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 96(1 Pt 1):155-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26115/abstract-text/7596706 /pubmed\" id=\"7596706 \" target=\"_blank\">",
"        7596706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13235 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26115=[""].join("\n");
var outline_f25_32_26115=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160824\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057939\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057933\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160810\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160796\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057943\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057936\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057942\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160844\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057946\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057932\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299205\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160807\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5026033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057938\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057931\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057945\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/42/9893?source=related_link\">",
"      Dimercaprol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35635?source=related_link\">",
"      Dimercaprol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26116="Tazarotene: Patient drug information";
var content_f25_32_26116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tazarotene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     see \"Tazarotene: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/60/3012?source=see_link\">",
"     see \"Tazarotene: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avage&reg;;",
"     </li>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tazorac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the number of wrinkles and liver spots.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702987",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tazarotene, vitamin A, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are sunburned.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eczema, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696955",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some weather conditions may irritate your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin may look worse before it looks better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman of childbearing age, take a pregnancy test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Practice good skin care and avoid the sun.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11876 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26116=[""].join("\n");
var outline_f25_32_26116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224840\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224841\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017519\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017518\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017523\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017524\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017526\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017521\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017522\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017527\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017528\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=related_link\">",
"      Tazarotene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/60/3012?source=related_link\">",
"      Tazarotene: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26117="Meconium myonecrosis";
var content_f25_32_26117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Meconium myonecrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Black arrow shows orangophilic apoptotic smooth muscle cell, and red arrow shows meconium pigment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla Roberts, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26117=[""].join("\n");
var outline_f25_32_26117=null;
var title_f25_32_26118="Phentermine: Drug information";
var content_f25_32_26118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phentermine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/41/20117?source=see_link\">",
"    see \"Phentermine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adipex-P&reg;;",
"     </li>",
"     <li>",
"      Suprenza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing is presented in terms of the salt, phentermine hydrochloride (not as phentermine base).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Obesity (short-term adjunct):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule, tablet: 15-37.5 mg/day given in 1-2 divided doses. Individualize to achieve adequate response with lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orally disintegrating tablet (ODT): One tablet (15 mg or 30 mg) every morning. Individualize to achieve adequate response with lowest effective dose.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4092487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14264939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied). Phentermine is excreted in the urine and systemic exposure may be increased in renal impairment; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14264940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 15 mg, 30 mg, 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adipex-P&reg;: 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 37.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adipex-P&reg;: 37.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suprenza&trade;: 15 mg, 30 mg [contains tartrazine; peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F209170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4092489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid late evening administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules, tablets: Administer before breakfast or 1-2 hours after breakfast. Tablets may be divided in half and dose may be given in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally disintegrating tablets (Suprenza&trade;):  With dry hands, place tablet on the tongue and allow to dissolve, then swallow with or without water. May administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (few weeks) adjunct therapy in obese patients with an initial body mass index (BMI) &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     or &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the presence of other risk factors (eg, diabetes, hyperlipidemia, controlled hypertension); therapy should be used in conjunction with a comprehensive weight management program.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phentermine may be confused with phentolamine, phenytoin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular:  Hypertension, ischemic events, palpitation, primary pulmonary hypertension and/or regurgitant cardiac valvular disease,  tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, dysphoria, euphoria, headache, insomnia, overstimulation, psychosis, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Changes in libido",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, unpleasant taste, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to phentermine or other sympathomimetic amines or any component of the formulation; history of cardiovascular disease (arrhythmias, congestive heart failure, coronary artery disease, stroke, uncontrolled hypertension); hyperthyroidism, glaucoma, agitated states, history of drug abuse; use during or within 14 days following MAO inhibitor therapy; pregnancy, breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Primary pulmonary hypertension (PPH): A rare, frequently fatal disease of the lungs, PPH has been reported to occur in patients receiving a combination of phentermine and fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; rare cases of PPH have been reported in patients taking phentermine alone. Discontinue in patients experiencing new-onset dyspnea, chest pain, syncope, or lower extremity edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valvular heart disease: The use of some anorexigens, including phentermine, has been associated with the development of valvular heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Avoid stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements (eg, insulin or oral hypoglycemic agents) may be decreased with anorexigens and concomitant dietary restrictions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with mild hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patients with renal impairment; use has not been studied; however, an increase in exposure is expected in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anorexigens: Safety and efficacy have not been established for use with other weight loss medications, including SSRIs, over-the-counter, or herbal products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to the risk for causing dependence, hypertension, angina, and myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential: Phentermine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Discontinue if weight loss has not occurred within the first 4 weeks of treatment (NHLBI, 1998). Phentermine is not approved for long-term use. The limited usefulness of medications in this class should be weighed against possible risks associated with their use. Consult weight loss guidelines for current pharmacotherapy recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Tolerance to the anorectic effect usually develops within a few weeks; discontinue use when tolerance develops, do not exceed recommended dosage in an attempt to overcome tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Phentermine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10515288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Concurrent use of phentermine with ethanol may result in adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4104669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use is contraindicated during pregnancy. The risks of using appetite suppressing drugs in pregnant women are not known and limited information is available about the use of phentermine in pregnancy. Weight loss therapy is generally not recommended for pregnant women. Obese and overweight women should be encouraged to participate in weight reduction programs prior to attempting pregnancy; weight gain during pregnancy should be determined by their prepregnancy BMI and current guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10515286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10515287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if phentermine is excreted in breast milk; however, other amphetamines have been detected in breast milk. Use is contraindicated in breast-feeding women. Weight loss therapy is generally not recommended for lactating women. Weight loss programs which include physical activity and nutrition components should be discussed at the 6-week postpartum visit.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4092488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules, tablets: Should be taken before breakfast or 1-2 hours after breakfast; avoid taking in the late evening. Most effective when combined with a low-calorie diet and behavior modification counseling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F209138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Adipex-P Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (100): $254.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Phentermine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $125.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $118.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (100): $157.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Suprenza Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (30): $59.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (30): $89.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (30): $98.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Adipex-P Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (100): $249.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Phentermine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     37.5 mg (100): $152.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weight, waist circumference; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4092486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult classification of weight by BMI (kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Underweight: &lt;18.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normal: 18.5-24.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Overweight: 25-29.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class I: 30-34.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class II: 35-39.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extreme obesity (class III): &ge;40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Waist circumference: In adults with a BMI of 25-34.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , high-risk waist circumference is defined as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Men &gt;102 cm (&gt;40 in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Women &gt;88 cm (&gt;35 in)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F209139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adipex (CH, KP);",
"     </li>",
"     <li>",
"      Adipex Retard (AT, CZ);",
"     </li>",
"     <li>",
"      Dietamin (KP);",
"     </li>",
"     <li>",
"      Duromine (AU, BB, BF, BJ, BM, BS, BZ, CI, CR, CY, DO, ET, GB, GH, GM, GN, GT, GY, HK, HN, IE, JM, KE, KW, LB, LR, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NZ, PA, PH, PR, SC, SD, SG, SL, SN, SR, SV, TH, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Furimin (KP);",
"     </li>",
"     <li>",
"      Ionamin (BE, IE, LU);",
"     </li>",
"     <li>",
"      Ionamine (CH);",
"     </li>",
"     <li>",
"      Jonamin (AU);",
"     </li>",
"     <li>",
"      Metermine (AU);",
"     </li>",
"     <li>",
"      Mirapront (IT);",
"     </li>",
"     <li>",
"      Mirubal (VE);",
"     </li>",
"     <li>",
"      Normaform (CH);",
"     </li>",
"     <li>",
"      Panbesy (BE, LU);",
"     </li>",
"     <li>",
"      Pender (KP);",
"     </li>",
"     <li>",
"      Phenkin (KP);",
"     </li>",
"     <li>",
"      Razin (IL);",
"     </li>",
"     <li>",
"      Sinpet (MX);",
"     </li>",
"     <li>",
"      Terfamex (CR, DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Vitupen (KP);",
"     </li>",
"     <li>",
"      Weltmine (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phentermine is a sympathomimetic amine with pharmacologic properties similar to the amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Orally disintegrating tablet: 3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abenhaim L, Moride Y, Brenot F, et al, &ldquo;Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. International Primary Pulmonary Hypertension Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(9):609-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/8692238/pubmed\" id=\"8692238\" target=\"_blank\">",
"        8692238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults,&rdquo;",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1998, 68(4):899-917.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/9771869/pubmed\" id=\"9771869\" target=\"_blank\">",
"        9771869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devan GS, &ldquo;Phentermine and Psychosis,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1990, 156:442-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/2346853/pubmed\" id=\"2346853\" target=\"_blank\">",
"        2346853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamer R and Phelps D, &ldquo;Inadvertent Intra-arterial Injection of Phentermine: A Complication of Drug Abuse,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1981, 10:148-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/7469155/pubmed\" id=\"7469155\" target=\"_blank\">",
"        7469155",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kokkinos J and Levine SR, &ldquo;Possible Association of Ischemic Stroke With Phentermine,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 1993, 24(2):310-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/8421834/pubmed\" id=\"8421834\" target=\"_blank\">",
"        8421834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine B, Caplan YH, and Dixon AM, &ldquo;A Fatality Involving Phentermine,&rdquo;",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1984, 29(4):1242-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/6502120/pubmed\" id=\"6502120\" target=\"_blank\">",
"        6502120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute Obesity Education Initiative, &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report,&rdquo;",
"      <i>",
"       NIH Publication",
"      </i>",
"      No. 98-4083. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothman RB and Baumann MH. \"Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2009, 16(4):354-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/19092640/pubmed\" id=\"19092640\" target=\"_blank\">",
"        19092640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(7):525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/15809464/pubmed\" id=\"15809464\" target=\"_blank\">",
"        15809464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thurman EM, Pedersen MJ, Stout RL, et al, &ldquo;Distinguishing Sympathomimetic Amines from Amphetamine and Methamphetamine in Urine by Gas Chromatography/Mass Spectrometry,&rdquo;",
"      <i>",
"       J Anal Toxicol",
"      </i>",
"      , 1992, 16(1):19-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/1640694/pubmed\" id=\"1640694\" target=\"_blank\">",
"        1640694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(11):933-49",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26118/abstract-text/14644896/pubmed\" id=\"14644896\" target=\"_blank\">",
"        14644896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9765 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3A9BE56C6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26118=[""].join("\n");
var outline_f25_32_26118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209168\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209150\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092487\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209151\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264939\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14264940\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209131\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209116\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209170\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092489\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209132\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209177\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209166\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209136\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209120\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299866\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209125\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10515288\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209126\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104669\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10515286\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10515287\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092488\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209138\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092486\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209139\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209119\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209135\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/41/20117?source=related_link\">",
"      Phentermine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26119="Physiologic and pathophysiologic consequences of mechanical ventilation";
var content_f25_32_26119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiologic and pathophysiologic consequences of mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26119/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/32/26119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation can be performed using positive pressure or negative pressure. Positive pressure ventilation is the primary type of mechanical ventilation used today. During positive pressure ventilation, the ventilator forces air into the central airways and the resulting pressure gradient causes airflow into the small airways and alveoli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of mechanical ventilation\", section on 'Types of breaths'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physiologic and pathophysiologic consequences of positive pressure ventilation are discussed in this topic review. Two major consequences of positive pressure ventilation, pulmonary barotrauma and ventilator-associated lung injury, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PULMONARY EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary barotrauma is a well-known complication of positive pressure ventilation. Consequences include pneumothorax, subcutaneous emphysema, pneumomediastinum, and pneumoperitoneum. Pulmonary barotrauma during mechanical ventilation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventilator-associated lung injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilator-associated lung injury (VALI) refers to acute lung injury that occurs during mechanical ventilation. It is clinically indistinguishable from acute lung injury or acute respiratory distress syndrome",
"    <span class=\"nowrap\">",
"     (ALI/ARDS)",
"    </span>",
"    due to other causes. VALI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Auto-PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auto-positive end-expiratory pressure (auto-PEEP, also called intrinsic PEEP) exists when there is positive airway pressure at the end of expiration due to incomplete exhalation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/1\">",
"     1",
"    </a>",
"    ]. In other words, inspiration is initiated before expiratory airflow from the preceding breath has ceased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous reasons that patients receiving positive pressure ventilation are susceptible to developing auto-PEEP (",
"    <a class=\"graphic graphic_table graphicRef57908 \" href=\"UTD.htm?17/10/17580\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High minute volume &ndash; High minute volume ventilation exists when there are large tidal volumes (greater than the patient's functional residual capacity), a high respiratory rate, or both. Large tidal volumes increase the volume that must be exhaled prior to the next breath. High respiratory rates decrease the duration of expiration. In both situations, the next breath is initiated prior to completion of the last exhalation. A high minute volume may be due to patient factors (eg, fever, infection) or ventilator settings.",
"     </li>",
"     <li>",
"      Prolonged inspiratory time &ndash; Prolonging the inspiratory time can be used to improve oxygenation in patients with refractory hypoxemia. When the inspiratory time is increased, there is an obligatory decrease in the expiratory time. This can lead to incomplete exhalation and auto-PEEP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Time-constant inequality &ndash; Patients whose lung units empty heterogeneously (eg, patients with obstructive airways disease) are particularly susceptible to developing auto-PEEP during positive pressure ventilation, even at relatively low minute ventilation.",
"     </li>",
"     <li>",
"      Expiratory flow resistance &ndash; Resistance to airflow (eg, narrow endotracheal tube, ventilator tubing) can cause auto-PEEP by impairing exhalation.",
"     </li>",
"     <li>",
"      Expiratory flow limitation (eg, obstructive airways disease) and altered respiratory system compliance (eg, expiratory muscle activity) similarly impede exhalation, causing auto-PEEP. Altered respiratory system compliance may also interfere with accurate measurement of auto-PEEP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auto-PEEP can be identified by applying an expiratory breath hold (usually 0.5 to 1 second) and then directly measuring the airway pressure at the end of the breath hold (",
"    <a class=\"graphic graphic_figure graphicRef52820 \" href=\"UTD.htm?24/62/25582\">",
"     figure 1",
"    </a>",
"    ). It can also be identified when ventilator waveforms, auscultation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpation demonstrate continued expiratory airflow from the preceding breath when the next breath is triggered. In a study of 73 patients (503 observations), physical examination identified auto-PEEP with positive and negative predictive values of 95 and 58 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/5\">",
"     5",
"    </a>",
"    ]. This indicates that physical examination is useful for confirming auto-PEEP, but not for excluding auto-PEEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auto-PEEP exacerbates the hemodynamic effects of positive pressure ventilation (discussed below), increases the risk of pulmonary barotrauma, and makes it more difficult for the patient to trigger a ventilator-assisted breath (",
"    <a class=\"graphic graphic_figure graphicRef64640 \" href=\"UTD.htm?17/34/17966\">",
"     figure 2",
"    </a>",
"    ). In addition, auto-PEEP can lead to incorrect estimation of the mean alveolar pressure and static lung compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate intervention is necessary if significant auto-PEEP is detected (",
"    <a class=\"graphic graphic_table graphicRef62376 \" href=\"UTD.htm?15/10/15531\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Change ventilator settings &ndash; The ventilator settings should be changed in an effort to reduce or eliminate auto-PEEP. The most helpful maneuvers are those that increase the duration of expiration: increasing the inspiratory flow rate, decreasing the respiratory rate, or both. Decreasing the tidal volume or using applied PEEP to overcome auto-PEEP may also be helpful. The use of applied PEEP in this setting is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H16#H16\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduce ventilatory demand &ndash; Ventilatory demand can be decreased by reducing carbohydrate intake, anxiety, pain, or fever. This may decrease the minute volume, thereby reducing auto-PEEP.",
"     </li>",
"     <li>",
"      Reduce expiratory flow resistance &ndash; Reduction of expiratory flow resistance by suctioning, administration of bronchodilators, and use of a wide endotracheal tube can reduce auto-PEEP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heterogeneous ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of positive pressure ventilation is never uniform because the amount of ventilation is a function of three factors that vary from region to region within the lungs: alveolar compliance, airway resistance, and dependency (upper versus lower lung zones). Compliant, non-dependent regions with minimal airway resistance will be best ventilated. In contrast, stiff, dependent regions with increased airway resistance will be least ventilated. The heterogeneity of ventilation is accentuated in patients who have both airways disease and parenchymal lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physiologic dead space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic dead space is the alveolar area that is not involved in gas exchange because of insufficient perfusion. Positive pressure ventilation tends to increase physiologic dead space by increasing ventilation in some regions without a corresponding increase in perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physiologic shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physiologic shunt exists where there is blood flow through pulmonary parenchyma that is not involved in gas exchange because of insufficient ventilation. Patients with respiratory failure frequently have increased physiologic shunting due to focal atelectasis without a corresponding decrease in perfusion. The focal atelectasis develops because dependent lung is no longer pulled open due to decreased diaphragmatic contraction. Positive pressure ventilation can mitigate physiologic shunting by increasing the mean airway pressure, which helps maintain airway and alveolar patency. This is particularly true if positive end-expiratory pressure (PEEP) is added. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diaphragm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled mechanical ventilation may lead to a very rapid type of disuse atrophy involving the diaphragmatic muscle fibers, which can develop within the first day of mechanical ventilation. An observational study of 22 patients compared the size of diaphragmatic muscle fibers from patients who received positive pressure ventilation for more than 18 hours to those from patients who received positive pressure ventilation for fewer than three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/7\">",
"     7",
"    </a>",
"    ]. The mean cross sectional area of both fast twitch diaphragmatic muscle fibers (1871 versus 3949 micron2) and slow twitch diaphragmatic muscle fibers (2025 versus 4725 micron2) was significantly smaller among those patients who received positive pressure ventilation for a longer duration. These findings were supported by a subsequent study that found that diaphragmatic strength decreased progressively during mechanical ventilation and that long-term mechanical ventilation (defined as &gt;24 hours) was associated with diaphragmatic muscle injury, atrophy, and proteolysis compared to short-term mechanical ventilation (defined as two to three hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Respiratory muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle atrophy can develop in patients undergoing positive pressure ventilation. The mechanism of respiratory muscle weakness is probably similar to that of general neuromuscular weakness in critically ill patients, which is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mucociliary motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation appears to impair mucociliary motility in the airways. In a series of 32 patients, bronchial mucus transport velocity was measured using technetium 99m-labeled albumin microspheres during the first three days of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/9\">",
"     9",
"    </a>",
"    ]. Bronchial mucus transport was frequently impaired and associated with retention of secretions and pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SYSTEMIC EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation frequently decreases cardiac output, which may cause hypotension. There are several mechanisms that contribute to the fall in cardiac output:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased venous return &ndash; The amount of venous return is determined by the pressure gradient from the extrathoracic systemic veins to the right atrium. Intrathoracic and right atrial pressure increase during positive pressure ventilation, thereby reducing the gradient for venous return. This effect is accentuated by auto-PEEP, applied PEEP, or intravascular hypovolemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced right ventricular output &ndash; Alveolar inflation during positive pressure ventilation compresses the pulmonary vascular bed. This increases pulmonary vascular resistance, thereby reducing right ventricular output. In a study of 21 patients with acute respiratory distress syndrome (ARDS), titrating the PEEP from 5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O to achieve a plateau pressure of 30 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O was associated with a fall in cardiac output and an increase in right ventricular afterload [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/11\">",
"       11",
"      </a>",
"      ]. This effect was mitigated by increasing the central venous blood volume via a passive leg raise maneuver.",
"     </li>",
"     <li>",
"      Reduced left ventricular output &ndash; Increased pulmonary vascular resistance can shift the interventricular septum to the left, impair diastolic filling of the left ventricle, and reduce left ventricular output.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these adverse effects, positive pressure ventilation may be beneficial in patients with left ventricular failure. Specifically, increased intrathoracic pressure can improve left ventricular performance by decreasing both venous return and left ventricular afterload [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These hemodynamic effects are the result of positive airway pressure being transmitted to the surrounding structures of the thorax. The extent to which this occurs varies according to chest wall and lung compliance. Transmission of airway pressure is greatest when there is low chest wall compliance (eg, fibrothorax) or high lung compliance (eg, emphysema); it is least when there is high chest wall compliance (eg, sternotomy) or low lung compliance (eg, ARDS, heart failure).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another consequence of positive airway pressure being transmitted to surrounding intrathoracic structures is that hemodynamic measurements may be artificially elevated. PEEP plays a particularly prominent role because most hemodynamic measurements are performed at the end of expiration when PEEP is the primary source of positive airway pressure.",
"   </p>",
"   <p>",
"    The effect of positive pressure ventilation on hemodynamic measures has been best studied using the pulmonary capillary wedge pressure (PCWP), although it appears to have a similar impact on the central venous pressure (CVP). The PCWP is measured by a pulmonary artery catheter (Swan-Ganz catheter). When a patient is receiving positive pressure ventilation, the PCWP is artificially elevated and not reflective of the true transmural filling pressure.",
"   </p>",
"   <p>",
"    The true transmural filling pressure can be estimated by subtracting one-half of the PEEP level from the PCWP if the lung compliance is normal, or one-quarter of the PEEP level if lung compliance is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, for a patient with normal lung compliance who is receiving a PEEP of 12 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and whose PCWP is measured as 18 mmHg, the true PCWP is estimated to be 12 mmHg.",
"   </p>",
"   <p>",
"    A more precise way to estimate the true transmural PCWP in patients requiring positive pressure ventilation utilizes the respiratory related variation of PCWP to estimate the transmission of alveolar pressure to the pulmonary vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/14\">",
"     14",
"    </a>",
"    ]. This measure is called the index of transmission:",
"   </p>",
"   <p>",
"    Index of transmission =",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(end inspiratory PCWP - end expiratory PCWP)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    (plateau airway pressure - total PEEP)",
"   </p>",
"   <p>",
"    Measurement of the plateau airway pressure is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary barotrauma during mechanical ventilation\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the index of transmission is calculated, the true PCWP can be estimated:",
"   </p>",
"   <p>",
"    Transmural PCWP =",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;end-expiratory PCWP - (index of transmission x total PEEP)",
"   </p>",
"   <p>",
"    This estimate may be unreliable if the respiratory variation of the PCWP is greater than that of the pulmonary arterial pressure tracing (",
"    <a class=\"graphic graphic_figure graphicRef62645 \" href=\"UTD.htm?11/26/11681\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation for greater than 48 hours is a risk factor for clinically important GI bleeding due to stress ulceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive airway pressure (especially PEEP) is also associated with decreased splanchnic perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/16\">",
"     16",
"    </a>",
"    ]. The mechanism underlying this association is unknown, but may be related to decreased cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/17\">",
"     17",
"    </a>",
"    ]. Decreased splanchnic perfusion manifests as elevated plasma aminotransferase and lactate dehydrogenase levels.",
"   </p>",
"   <p>",
"    Other gastrointestinal complications seen in patients receiving positive pressure ventilation include erosive esophagitis, diarrhea, acalculous cholecystitis, and hypomotility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is uncertain whether these complications are due to mechanical ventilation or the critical illness. Hypomotility usually manifests as intolerance to enteral feeding. Correction of electrolytic abnormalities and avoidance of drugs that adversely affect gastric motility (eg, opiates) can improve gastrointestinal motility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation is associated with the development of acute renal failure. In a prospective cohort study of 29,269 critically ill patients, positive pressure ventilation was an independent risk factor for acute renal failure (odds ratio 2.11, 95% CI 1.58-2.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/20\">",
"     20",
"    </a>",
"    ]. The mechanism for renal injury during positive pressure ventilation is unknown, but it is likely multifactorial. Hypotheses include renal injury through the release of inflammatory mediators (eg, interleukin-6) and impaired renal blood flow due to decreased cardiac output, increased sympathetic tone, or activation of humoral pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation increases intracranial pressure (ICP). This is probably the result of elevated intrathoracic pressure impairing cerebral venous outflow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic muscular weakness is common among patients who undergo mechanical ventilation. Potential causes include immobilization, prolonged use of sedatives, use of neuromuscular blocking agents, and critical illness. It is unknown whether the mechanical ventilation can cause systemic weakness independently.",
"   </p>",
"   <p>",
"    Weakness is associated with long-term disability and the need for protracted rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/22\">",
"     22",
"    </a>",
"    ]. However, early mobilization and exercise (ie, physical and occupational therapy) may increase the likelihood that a patient will return to an independent functional status. This was best demonstrated by a trial that randomly assigned 104 patients to either standard care or mobilization plus exercise beginning within 72 hours of the initiation of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients who received mobilization and exercise were more likely to return to an independent functional status by hospital discharge (59 versus 35 percent, odds ratio 2.7, 95% CI 1.2-6.1).",
"   </p>",
"   <p>",
"    The causes, diagnosis, and management of systemic weakness in patients in the ICU are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=see_link\">",
"     \"Neuromuscular weakness related to critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive pressure ventilation appears to induce inflammation. In a randomized trial of 44 patients, patients who received positive pressure ventilation using large tidal volumes and low PEEP had higher concentrations of inflammatory mediators in their blood and bronchoalveolar lavage fluid than patients who received a smaller tidal volumes and high PEEP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive pressure ventilation may also promote translocation of tracheal bacteria into the bloodstream, according to one animal study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/25\">",
"     25",
"    </a>",
"    ]. Translocation was most pronounced during ventilation with large tidal volumes and low PEEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disordered sleep is common among patients in the intensive care unit. This was illustrated by a prospective cohort study of 20 patients who were being mechanically ventilated for acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/26\">",
"     26",
"    </a>",
"    ]. None of the patients experienced normal sleep according to 24-hour polysomnography.",
"   </p>",
"   <p>",
"    Environmental, disease-related, and treatment-related factors have been proposed as possible causes of the disordered sleep seen in critically ill patients. Among these factors, environmental factors may be the least important. This was demonstrated by a study that assessed seven mechanically ventilated patients and six healthy subjects in the intensive care unit using both 24-hour polysomnography and time synchronized environmental monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/27\">",
"     27",
"    </a>",
"    ]. Patient care activities and noise accounted for less than 30 percent of arousals and awakenings.",
"   </p>",
"   <p>",
"    The mode of mechanical ventilation may also influence sleep quality, particularly pressure support ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, this has not been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness is not the only consequence of prolonged bedrest. Prolonged bedrest has also been associated with insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/30\">",
"     30",
"    </a>",
"    ], venous thromboembolic disease, and joint contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/31\">",
"     31",
"    </a>",
"    ]. During mechanical ventilation, the head of the bed is frequently raised to prevent aspiration and ventilator-acquired pneumonia, which may increase the risk of sacral pressure ulcers by increasing the pressure on the skin in the sacral region [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26119/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse pulmonary effects of positive pressure ventilation include pulmonary barotrauma, ventilator-associated lung injury, intrinsic positive end expiratory pressure (auto-PEEP), heterogeneous ventilation, increased physiologic dead space, decreased physiologic shunting, diaphragmatic muscle atrophy, respiratory muscle weakness, and diminished mucociliary motility. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pulmonary effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Auto-PEEP exists when there is positive airway pressure at the end of expiration due to incomplete exhalation. It exacerbates the hemodynamic effects of positive pressure ventilation, increases the risk of pulmonary barotrauma, and makes it more difficult for the patient to trigger a ventilator-assisted breath. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Auto-PEEP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of auto-PEEP should prompt immediate ventilator setting changes, efforts to reduce ventilatory demand, and efforts to reduce expiratory flow resistance (",
"      <a class=\"graphic graphic_table graphicRef62376 \" href=\"UTD.htm?15/10/15531\">",
"       table 2",
"      </a>",
"      ). The most helpful maneuvers are those that increase the duration of expiration: increasing the inspiratory flow rate, decreasing the respiratory rate, or both. Decreasing the tidal volume or using applied PEEP to overcome auto-PEEP may also be helpful. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Auto-PEEP'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H17#H17\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Applied PEEP'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Positive pressure ventilation may reduce cardiac output and impair hemodynamic monitoring. In addition, it is associated with gastrointestinal stress ulceration, decreased splanchnic perfusion, gastrointestinal hypomotility, fluid retention, acute renal failure, increased intracranial pressure, weakness, inflammation, and disordered sleep. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Systemic effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/1\">",
"      Pepe PE, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect. Am Rev Respir Dis 1982; 126:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/2\">",
"      Rossi A, Polese G, Brandi G, Conti G. Intrinsic positive end-expiratory pressure (PEEPi). Intensive Care Med 1995; 21:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/3\">",
"      Younes M, Kun J, Webster K, Roberts D. Response of ventilator-dependent patients to delayed opening of exhalation valve. Am J Respir Crit Care Med 2002; 166:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/4\">",
"      Lessard MR, Lofaso F, Brochard L. Expiratory muscle activity increases intrinsic positive end-expiratory pressure independently of dynamic hyperinflation in mechanically ventilated patients. Am J Respir Crit Care Med 1995; 151:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/5\">",
"      Kress JP, O'Connor MF, Schmidt GA. Clinical examination reliably detects intrinsic positive end-expiratory pressure in critically ill, mechanically ventilated patients. Am J Respir Crit Care Med 1999; 159:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/6\">",
"      Valta P, Corbeil C, Chass&eacute; M, et al. Mean airway pressure as an index of mean alveolar pressure. Am J Respir Crit Care Med 1996; 153:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/7\">",
"      Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008; 358:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/8\">",
"      Jaber S, Petrof BJ, Jung B, et al. Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med 2011; 183:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/9\">",
"      Konrad F, Schreiber T, Brecht-Kraus D, Georgieff M. Mucociliary transport in ICU patients. Chest 1994; 105:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/10\">",
"      Qvist J, Pontoppidan H, Wilson RS, et al. Hemodynamic responses to mechanical ventilation with PEEP: the effect of hypervolemia. Anesthesiology 1975; 42:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/11\">",
"      Foug&egrave;res E, Teboul JL, Richard C, et al. Hemodynamic impact of a positive end-expiratory pressure setting in acute respiratory distress syndrome: importance of the volume status. Crit Care Med 2010; 38:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/12\">",
"      Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N Engl J Med 1991; 325:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/13\">",
"      Marini JJ, O'Quin R, Culver BH, Butler J. Estimation of transmural cardiac pressures during ventilation with PEEP. J Appl Physiol 1982; 53:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/14\">",
"      Teboul JL, Pinsky MR, Mercat A, et al. Estimating cardiac filling pressure in mechanically ventilated patients with hyperinflation. Crit Care Med 2000; 28:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/15\">",
"      Teboul, JL, Besbes, M, Andrivet, P, et al. A bedside index assessing the reliability of pulmonary artery occlusion pressure measurements during mechanical ventilation with positive end-expiratory pressure. J Crit Care 1992; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/16\">",
"      De Backer D. The effects of positive end-expiratory pressure on the splanchnic circulation. Intensive Care Med 2000; 26:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/17\">",
"      Kiefer P, Nunes S, Kosonen P, Takala J. Effect of positive end-expiratory pressure on splanchnic perfusion in acute lung injury. Intensive Care Med 2000; 26:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/18\">",
"      Dive A, Moulart M, Jonard P, et al. Gastroduodenal motility in mechanically ventilated critically ill patients: a manometric study. Crit Care Med 1994; 22:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/19\">",
"      Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest 2001; 119:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/20\">",
"      Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/21\">",
"      Kuiper JW, Groeneveld AB, Slutsky AS, Pl&ouml;tz FB. Mechanical ventilation and acute renal failure. Crit Care Med 2005; 33:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/22\">",
"      Schweickert WD, Hall J. ICU-acquired weakness. Chest 2007; 131:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/23\">",
"      Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009; 373:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/24\">",
"      Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999; 282:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/25\">",
"      Nahum A, Hoyt J, Schmitz L, et al. Effect of mechanical ventilation strategy on dissemination of intratracheally instilled Escherichia coli in dogs. Crit Care Med 1997; 25:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/26\">",
"      Cooper AB, Thornley KS, Young GB, et al. Sleep in critically ill patients requiring mechanical ventilation. Chest 2000; 117:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/27\">",
"      Gabor JY, Cooper AB, Crombach SA, et al. Contribution of the intensive care unit environment to sleep disruption in mechanically ventilated patients and healthy subjects. Am J Respir Crit Care Med 2003; 167:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/28\">",
"      Parthasarathy S, Tobin MJ. Effect of ventilator mode on sleep quality in critically ill patients. Am J Respir Crit Care Med 2002; 166:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/29\">",
"      Cabello B, Thille AW, Drouot X, et al. Sleep quality in mechanically ventilated patients: comparison of three ventilatory modes. Crit Care Med 2008; 36:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/30\">",
"      Hamburg NM, McMackin CJ, Huang AL, et al. Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers. Arterioscler Thromb Vasc Biol 2007; 27:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/31\">",
"      Clavet H, H&eacute;bert PC, Fergusson D, et al. Joint contracture following prolonged stay in the intensive care unit. CMAJ 2008; 178:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26119/abstract/32\">",
"      Peterson M, Schwab W, McCutcheon K, et al. Effects of elevating the head of bed on interface pressure in volunteers. Crit Care Med 2008; 36:3038.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1628 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26119=[""].join("\n");
var outline_f25_32_26119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PULMONARY EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Auto-PEEP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Consequences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heterogeneous ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physiologic dead space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physiologic shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Respiratory muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mucociliary motility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SYSTEMIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Immune system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1628|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/62/25582\" title=\"figure 1\">",
"      Auto PEEP effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/34/17966\" title=\"figure 2\">",
"      Auto PEEP trigger threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/26/11681\" title=\"figure 3\">",
"      PEEP and pulmonary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/10/17580\" title=\"table 1\">",
"      Hyperinflation and auto PEEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/10/15531\" title=\"table 2\">",
"      Treatment of auto PEEP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43976?source=related_link\">",
"      Neuromuscular weakness related to critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26120="Fluticasone (oral inhalation): Drug information";
var content_f25_32_26120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone (oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=see_link\">",
"    see \"Fluticasone (oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=see_link\">",
"    see \"Fluticasone (oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9349572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9349626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Inhalation, oral:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to the lowest effective dose once asthma stability is achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Flovent&reg; HFA:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     Dosing based on previous asthma therapy:",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after 2 weeks of therapy in patients who are not adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bronchodilator alone: Initial: 88 mcg twice daily; maximum: 440 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inhaled corticosteroids: Initial: 88-220 mcg twice daily (initial dose &gt;88 mcg twice daily may be considered in patients previously requiring higher doses of inhaled corticosteroids); maximum: 440 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral corticosteroids (OCS): Initial: 440 mcg twice daily; maximum: 880 mcg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 88-264 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;264-440 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;440 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after ~1 week of therapy in patients who are not adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild asthma: 100-250 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate asthma: 250-500 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe asthma: 500 mcg twice daily; may increase up to 1000 mcg twice daily in very severe patients (eg, patients using oral corticosteroids [OCS])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Flovent&reg; Diskus&reg;:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after 2 weeks of therapy in patients who are not adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dosing based on previous asthma therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Bronchodilator alone: Initial: 100 mcg twice daily; maximum: 500 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Inhaled corticosteroids: Initial: 100-250 mcg twice daily; maximum: 500 mcg twice daily; initial dose &gt;100 mcg twice daily may be considered in patients with poorer asthma control or those previously requiring high ranges of inhaled corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral corticosteroids (OCS): Initial: 500-1000 mcg twice daily; maximum: 1000 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 100-300 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;300-500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:10em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after ~1 week of therapy in patients who are not adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild asthma: 100-250 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate asthma: 250-500 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe asthma: 500 mcg twice daily; may increase up to 1000 mcg twice daily in very severe patients (eg, patients using oral corticosteroids [OCS])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroids to orally inhaled corticosteroids:",
"     </b>",
"     When converting from oral corticosteroids (OCS) to orally inhaled corticosteroids, initiate oral inhalation therapy in patients whose asthma is previously stabilized on OCS. Gradual OCS dose reductions should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than 2.5-5 mg/day (or equivalent of other OCS) weekly. The Canadian labeling recommends decreasing the  daily dose of prednisone by 1 mg (or equivalent of other OCS) no more rapidly than weekly in adults who are closely monitored or every 10 days if not closely monitored. If adrenal insufficiency occurs, resume OCS therapy; initiate a more gradual withdrawal. When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9349625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=see_link\">",
"      see \"Fluticasone (oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Inhalation, oral:",
"     <b>",
"      Note:",
"     </b>",
"     Titrate to lowest effective dose once asthma stability achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Flovent&reg; HFA:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      <b>",
"       <i>",
"        U.S. labeling:",
"       </i>",
"      </b>",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-11 years: Initial: 88 mcg twice daily; maximum: 88 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     0-4 years: 176 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     5-11 years: 88-176 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;12 years: 88-264 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     0-4 years: &gt;176-352 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     5-11 years: &gt;176-352 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;12 years: &gt;264-440 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     0-4 years: &gt;352 mcg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     5-11 years: &gt;352 mcg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     &ge;12 years: &gt;440 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      <b>",
"       <i>",
"        Canadian labeling:",
"       </i>",
"      </b>",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-3 years:  100 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-15 years: 100 mcg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends Flovent&reg; HFA be administered as a minimum of 2 inhalations twice daily; therefore,  patients  requiring lower or higher dosages than 100 mg twice daily should use Flovent&reg; Diskus&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;16 years and Adults: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Flovent&reg; Diskus&reg;:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      <b>",
"       <i>",
"        U.S. labeling:",
"       </i>",
"      </b>",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-11 years: Initial: 50 mcg twice daily; may increase to maximum dose of 100 mcg twice daily in patients not adequately controlled after 2 weeks of therapy. Initial dose &gt;50 mcg twice daily may be considered in patients with poorer asthma control or those previously requiring high ranges of inhaled corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     5-11 years: 100-200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;12 years: 100-300 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     5-11 years: &gt;200-400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ge;12 years: &gt;300-500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:10em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     5-11 years: &gt;400 mcg/day",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:8em;text-align:justify;\">",
"     &ge;12 years: &gt;500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      <b>",
"       <i>",
"        Canadian labeling:",
"       </i>",
"      </b>",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-16 years: Initial: 50-100 mcg twice daily; may increase up to 200 mcg twice daily after ~1 week of therapy in patients not adequately controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroids to orally inhaled corticosteroids:",
"     </b>",
"     When converting from oral corticosteroids (OCS) to orally inhaled corticosteroids, initiate oral inhalation therapy in patients whose asthma is previously stabilized on OCS. Gradual OCS dose reductions should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than 2.5-5 mg/day (or equivalent of other OCS) weekly in children &ge;12 years but does not provide a recommendation for children &lt;12 years. A similar approach to OCS dose reduction would however seem advisable. The Canadian labeling recommends decreasing the  daily dose of prednisone by 1 mg (or equivalent of other OCS) every 8 days in children who are closely monitored or every 20 days if not closely monitored. If adrenal insufficiency occurs, resume OCS therapy; initiate a more gradual withdrawal. When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9349627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14306518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9349628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); however, fluticasone is primarily cleared in the liver and plasma levels may be increased in patients with hepatic impairment. Use with caution; monitor.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; HFA: 44 mcg/inhalation (10.6 g); 110 mcg/inhalation (12 g); 220 mcg/inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 50 mcg (60s); 100 mcg (60s); 250 mcg (60s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9349666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; HFA:  50 mcg/inhalation (120 actuations); 125 mcg/inhalation (60 or 120 actuations); 250 mcg/inhalation (60 or 120 actuations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 50 mcg (60s) [contains lactose; prefilled blister pack]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 100 mcg (60s) [contains lactose; prefilled blister pack]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 250 mcg (60s) [contains lactose; prefilled blister pack]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 500 mcg (60s) [contains lactose; prefilled blister pack]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9349571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9349630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol inhalation: Flovent&reg; HFA: Shake container thoroughly before using. Take 3-5 deep breaths. Use inhaler on inspiration. Allow 1 full minute between inhalations. Rinse mouth with water after use to reduce aftertaste and incidence of candidiasis; do not swallow. Inhaler must be primed before first use, when not used for 7 days, or if dropped. To prime the first time, release 4 sprays into air; shake well before each spray and spray away from face. If dropped or not used for 7 days, prime by releasing a single test spray. Patient should contact pharmacy for refill when the dose counter reads &ldquo;020&rdquo;. Discard device when the dose counter reads &ldquo;000&rdquo;. Do not use &ldquo;float&rdquo; test to determine contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for oral inhalation: Flovent&reg; Diskus&reg;: Do not use with a spacer device. Do not exhale into Diskus&reg;. Do not wash or take apart. Use in horizontal position. Mouth should be rinsed with water after use (do not swallow). Discard after 6 weeks (50 mcg diskus) or after 2 months (100 mcg and 250 mcg diskus) once removed from protective pouch or when the dose counter reads &ldquo;0&rdquo;, whichever comes first (device is not reusable).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F242573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Maintenance treatment of asthma as prophylactic therapy; also indicated for patients requiring oral corticosteroid therapy for asthma to assist in total discontinuation or reduction of total oral dose",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9349564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flovent&reg; may be confused with Flonase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flovent [U.S., Canada] may be confused with Flogen brand name for naproxen [Mexico]; Flogene brand name for piroxicam [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9349582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Malaise/fatigue (16%), headache (2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Oral candidiasis (&le;31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia/articular rheumatism (17%), musculoskeletal pain (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis/sinus infection (&le;33%), upper respiratory tract infection (&le;31%), throat irritation (3% to 22%), nasal congestion/blockage (16%), rhinitis (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (10%), fever (1% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (8%), pruritus (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (1% to 9%), gastrointestinal infection (including viral; 1% to 5%), gastrointestinal discomfort/pain (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle injury (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hoarseness/dysphonia (2% to 9%), cough (1% to 9%), viral respiratory infection (1% to 9%),  bronchitis (&le;8%), upper respiratory tract inflammation (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Aggression, agitation, anaphylactic reaction (rare with both products; Diskus&reg; - some patients with severe milk allergy), angioedema, anxiety, aphonia, asthma exacerbation, behavioral changes (eg, hyperactivity and irritability in children; rare), bone mineral density decreased, bronchospasm (immediate and delayed), cataracts, chest tightness, Churg-Strauss syndrome, contusion, Cushingoid features, cutaneous hypersensitivity, depression, dyspnea, ecchymoses, eosinophilia, facial edema, growth velocity reduction in children/adolescents, HPA axis suppression, hyperglycemia, hypersensitivity reactions (immediate and delayed), laryngitis, migraine, muscle rigidity/stiffness/tightness, oropharyngeal edema, osteoporosis, paradoxical bronchospasm, pneumonia, restlessness, throat soreness, tooth discoloration, urticaria, vasculitis, wheeze",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9349579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluticasone or any component of the formulation; severe hypersensitivity to milk proteins or lactose (Flovent&reg; Diskus&reg;); primary treatment of status asthmaticus or other acute episodes of asthma requiring intensive measures",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Moderate-to-severe bronchiectasis; untreated fungal, bacterial or tubercular infections of the respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9349580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use in patients with ocular herpes or untreated viral, fungal, or bacterial or parasitic systemic infections (Canadian labeling contraindicates use with untreated respiratory infections). Exposure to chickenpox should be avoided. Close observation is required in patients with latent tuberculosis (TB) and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). With oral inhalation, local yeast infections (eg, oral pharyngeal candidiasis) may occur; patient should rinse mouth and spit after each use to reduce incidence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasculitis: Rare cases of vasculitis (Churg-Strauss syndrome) or other eosinophilic conditions can occur; often associated with decrease or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with strong CYP3A4 inhibitors is not recommended (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flovent&reg; Diskus&reg;: Contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9349607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9349606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9349611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: In theory, St John's wort may decrease serum levels of fluticasone by inducing CYP3A4 isoenzymes.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F242569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9349575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with systemic corticosteroids in animal reproduction studies. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9349577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9349578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of fluticasone are absorbed following inhalation to produce detectable amounts in breast milk. The use of inhaled corticosteroids is not considered a contraindication to breast feeding.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9349629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flovent&reg; Diskus&reg; contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9349664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Flovent HFA Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     44 mcg/ACT (10.6 g): $138.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     110 mcg/ACT (12 g): $185.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mcg/ACT (12 g): $287.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Flovent Diskus Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/blister (60): $131.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg/blister (60): $138.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg/blister (28): $134.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F242570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including Churg-Strauss syndrome); FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests; asthma symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atemur Mite (DE);",
"     </li>",
"     <li>",
"      Axotide (CH);",
"     </li>",
"     <li>",
"      Flixotaide (PT);",
"     </li>",
"     <li>",
"      Flixotide (AE, AR, AT, BE, BG, BH, BR, CL, CN, CR, CY, CZ, DK, EC, EE, EG, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LY, MY, NI, NL, NZ, OM, PA, PE, PH, PY, QA, RU, SA, SE, SG, SV, SY, TH, TT, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Flixotide Inhaler (AU);",
"     </li>",
"     <li>",
"      Flixotide Nebules (AU);",
"     </li>",
"     <li>",
"      Flutide (DE, NO);",
"     </li>",
"     <li>",
"      Flutimar HFA (CO);",
"     </li>",
"     <li>",
"      Fluzone (GT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F242564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity. The effectiveness of inhaled fluticasone is due to its direct local effect.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9349615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Maximal benefit may take 1-2 weeks or longer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Absorbed systemically (Flovent&reg; Diskus&reg;: ~8%) primarily via lungs, minimal GI absorption (&lt;1%) due to presystemic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 4.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to 17&beta;-carboxylic acid (negligible activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~11-12 hours (Thorsson, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as parent drug and metabolites); urine (&lt;5% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26120/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26120/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thorsson L, Edsb&auml;cker S, K&auml;ll&eacute;n, et al, &ldquo;Pharmacokinetics and Systemic Activity of Fluticasone via Diskus&reg; and pMDI, and of Budesonide via Turbuhaler&reg;,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2001, 52(5): 529-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26120/abstract-text/11736861/pubmed\" id=\"11736861\" target=\"_blank\">",
"        11736861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Buck JJ, et al, \"Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2002, 19(6):1207-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26120/abstract-text/12108877/pubmed\" id=\"12108877\" target=\"_blank\">",
"        12108877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al, \"Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2002, 87(6):457-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/32/26120/abstract-text/12456538/pubmed\" id=\"12456538\" target=\"_blank\">",
"        12456538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9136 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26120=[""].join("\n");
var outline_f25_32_26120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349568\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349569\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349572\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349626\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349625\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349627\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14306518\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349628\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242572\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349666\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349571\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349630\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242573\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349582\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349579\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349580\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349607\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349611\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242569\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349575\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349577\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349578\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349629\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349664\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242570\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707662\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242564\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349615\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/29/25047?source=related_link\">",
"      Fluticasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26121="Airway complications after lung transplantation";
var content_f25_32_26121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Airway complications after lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Marcelo Cypel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Tom Waddell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Shaf Keshavjee, MD, MSc, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26121/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/32/26121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During lung transplantation, the airway anastomosis is typically performed between the bronchus of the donor lung and that of the recipient. The airway anastomosis has traditionally been the most vulnerable site for operative complications of lung transplantation. Airway anastomotic complications include focal infection, bronchial necrosis and dehiscence, excess granulation tissue, tracheobronchomalacia, stenosis, and fistula formation.",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, treatment, and prevention of airway anastomotic complications of lung transplantation will be reviewed here. Other airway complications, such as bacterial and viral tracheobronchitis and bronchiolitis obliterans, and noninfectious problems related to lung transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=see_link\">",
"     \"Noninfectious complications following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anastomotic airway complications after lung transplantation include those that typically develop within the first month (eg, anastomotic infection, necrosis, or dehiscence) and those that develop later (eg, excess granulation tissue, bronchomalacia, airway stenosis, bronchopleural fistula, bronchomediastinal fistula, or bronchovascular fistula) (",
"    <a class=\"graphic graphic_table graphicRef70902 \" href=\"UTD.htm?37/34/38444\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited mucosal necrosis and sloughing at the anastomotic site are commonly observed during bronchoscopy in the first two to three weeks after transplant. These mild mucosal changes are not usually considered an \"airway complication,\" if satisfactory healing occurs without intervention. Complications are considered significant when they necessitate an intervention such as debridement, dilatation, or stent placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported incidences of airway anastomotic complications range from 2 to 33 percent, although most centers have rates in the range of 7 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a retrospective series of 232 lung transplants, 57 airway complications developed; the majority occurred in the first post-transplant year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although airway complications lead to increased costs, greater morbidity, and decreased quality of life, they are generally not associated with a substantial decrease in survival. In a series of 983 lung transplants, the hospital mortality of those with an airway complication was 10 versus 9.7 percent for those without an anastomotic complication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major reason for the high rate of complications at the bronchial anastomotic site is believed to be the loss of systemic blood supply to that site during transplantation. The normal bronchial blood supply is interrupted during the lung harvest procedure, leaving the bronchial vessels at the anastomotic site dependent on retrograde filling from the pulmonary arterial circulation through communications with pulmonary capillaries and precapillary anastomoses in the submucosal plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Revascularization of the donor bronchus usually takes two to four weeks. This process may be more successful when the donor bronchus is shortened to within one to two cartilaginous rings of the take-off of the upper lobe bronchus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/7\">",
"     7",
"    </a>",
"    ]. While revascularization is occurring, the anastomotic site is subject to ischemic conditions and may develop varying degrees of necrosis and dehiscence. In some patients, the healing process of these areas of necrosis leads to development of granulation tissue and subsequent airway stenosis.",
"   </p>",
"   <p>",
"    The surgical anastomotic technique may be a factor in the development of airway complications. The original technique of using an omentopexy (surrounding the anastomosis with a piece of omentum) was associated with a high rate of dehiscence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequent techniques have used a simple buttressing of the anastomosis with peribronchial tissues, which has decreased the rate of dehiscence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An aspect of the anastomotic technique that remains controversial is telescoping the anastomosis by preferentially intussuscepting the recipient bronchus into that of the donor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. This technique may reduce early dehiscence, but may lead to increased rates of bronchial stenosis months later [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. We typically use the end-to-end anastomotic technique and reserve the telescoping anastomotic technique for situations where there is a size discrepancy between the donor and recipient bronchi [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors are associated with an increased risk of anastomotic airway complications.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe reperfusion edema (primary graft dysfunction) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transplant rejection within first postoperative month [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pre and postoperative pulmonary infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,14\">",
"       1,14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Single lung transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Colonization with Aspergillus fumigatus [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preoperative Pseudomonas cepacia colonization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      prior to complete anastomotic healing [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Current doses of glucocorticoids used to suppress rejection are not felt to increase the risk of airway complications following lung transplantation, despite their adverse effects on wound healing in general.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AIRWAY SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform surveillance bronchoscopy with inspection of the anastomotic site at 2 weeks, 6 weeks, 3 months, and 6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. Bronchoscopy is also performed when symptoms suggest possible anastomotic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPECIFIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of the airway anastomotic complications varies, depending on the specific complication. Most of the post-transplant bronchial complications can be treated successfully with non-surgical interventions, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bronchial stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial stenosis is the most common airway complication and often occurs in patients who have experienced anastomotic necrosis, dehiscence, or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Bronchial stenosis usually manifests after the first posttransplant month, but sometimes not until years after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial stenosis can be asymptomatic and diagnosed as an incidental finding during surveillance bronchoscopy, or it may present with dyspnea, wheezing, stridor, deteriorating pulmonary function tests, or postobstructive pneumonia. When presenting years after transplantation, the stenosis can cause progressive, often debilitating airflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of bronchial stenosis is based upon bronchoscopic visualization. Computed tomography (CT), performed with multiplanar reconstruction of the bronchial tree or virtual bronchoscopy, is typically done to provide additional information regarding the exact location and length of the bronchial or anastomotic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirometry with flow-volume curves is used to assess the severity of airflow limitation. However, interpretation of spirometric results may be difficult in the setting of single lung transplantation for COPD as airflow obstruction may reflect the diseased native lung. Inspiratory and expiratory flow-volume curves help to distinguish between airflow obstruction caused by bronchial stenosis and that caused by bronchomalacia or bronchiolitis obliterans syndrome. Bronchial stenosis typically results in a pattern of fixed airflow limitation during both inspiration and expiration, while bronchomalacia has variable obstruction worse on expiration than inspiration (",
"    <a class=\"graphic graphic_figure graphicRef77738 \" href=\"UTD.htm?18/14/18669\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link&amp;anchor=H5#H5\">",
"     \"Flow-volume loops\", section on 'Variable intrathoracic obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link&amp;anchor=H9#H9\">",
"     \"Flow-volume loops\", section on 'Mainstem bronchial obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17194?source=see_link&amp;anchor=H11#H11\">",
"     \"Physiologic changes following lung transplantation\", section on 'Spirometry'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vanishing bronchus intermedius",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several cases have been reported of bronchial stenosis in the bronchus intermedius, distal to the anastomotic site [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/18\">",
"     18",
"    </a>",
"    ]. This type of stenosis is known as the vanishing bronchus intermedius syndrome. The time of diagnosis is usually between two and six months posttransplant, but may be as late as 12 months posttransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/18\">",
"     18",
"    </a>",
"    ]. Ischemic injury is believed to be the inciting factor, as ischemic changes in this area are often visible on posttransplant bronchoscopy. However, acute cellular rejection may also contribute.",
"   </p>",
"   <p>",
"    The diagnosis is typically made by fiberoptic bronchoscopy. Right middle and lower lobe collapse may be visible on chest radiography. A chest CT scan may be helpful to delineate the length of the obstruction. This type of bronchial stenosis is associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Management is similar to that for anastomotic stenosis, as described below, although it is difficult to keep a stent in the correct position without occlusion of the right upper lobe bronchus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild, asymptomatic bronchial stenosis (less than 50 percent of the bronchial diameter) can be managed conservatively with observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19\">",
"     19",
"    </a>",
"    ]. For more severe, symptomatic bronchial stenosis (usually greater than 50 percent of bronchial diameter), bronchoscopic dilation is the initial and preferred treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Alternative measures for refractory stenosis include laser or cryosurgery, placement of an endobronchial stent, sleeve resection of the stenotic area, lobectomy, and retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These choices are described further in the following paragraphs.",
"   </p>",
"   <p>",
"    Endobronchial dilation is usually accomplished with a rigid or a flexible bronchoscope using balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12,19,23-25\">",
"     12,19,23-25",
"    </a>",
"    ]. In a series of 17 patients with moderate to severe bronchial stenosis after lung transplant, 14 patients were managed successfully with airway dilation via flexible or rigid bronchoscopy, while two required pneumonectomy and one retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19\">",
"     19",
"    </a>",
"    ]. In the pediatric population, the balloon technique was found to be better for dilation, than using the rigid bronchoscope itself for dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12\">",
"     12",
"    </a>",
"    ]. If stenosis recurs, dilation is usually repeated as this is often successful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27126?source=see_link\">",
"     \"Flexible bronchoscopy balloon dilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Rigid or balloon dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients whose stenosis is fibrotic and poorly responsive to balloon dilation, laser or electrosurgery may be used to create radial incisions in the stricture prior to balloon dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,26\">",
"     1,26",
"    </a>",
"    ]. Laser or cryotherapy may also be used to treat granulation tissue developing at the site [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Laser therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Electrocautery and argon plasma coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The placement of endobronchial stents is reserved for cases of severe and refractory stenosis, as stents are associated with a high incidence of complications such as mucus impaction, granulation tissue formation, dislodgment, and migration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12,16,23,27,28\">",
"     12,16,23,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link&amp;anchor=H21536315#H21536315\">",
"     \"Airway stents\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stent placement is often performed under general anesthesia, using rigid bronchoscopy, and may be combined with a dilation procedure to enable placement of the largest stent possible. Self-expanding silicone stents are generally preferred over metallic stents because they are easily removable [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/29\">",
"     29",
"    </a>",
"    ]. In a series of 27 lung transplant recipients, silicone stents were placed in 32 stenotic airway lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/30\">",
"     30",
"    </a>",
"    ]. Stents were left in place for a median of 6 months (range 1 to 22 months). Occasionally, inspissated secretions in the stents required bronchoscopic removal. Formation of granulation tissue at either end of the stent was common, but rarely required additional intervention and typically resolved after stent removal. Silicone stents are usually left in place until the airway appears healed.",
"   </p>",
"   <p>",
"    Alternative stents, such as removable nitinol stents, are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link&amp;anchor=H5#H5\">",
"     \"Airway stents\", section on 'Silicone stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link&amp;anchor=H10#H10\">",
"     \"Airway stents\", section on 'Metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When attempts at dilation and stenting fail, surgical strategies include sleeve resection, lobe resection, and also retransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/19,22,33\">",
"     19,22,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=see_link&amp;anchor=H19#H19\">",
"     \"Lung transplantation: Procedure and postoperative management\", section on 'Retransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anastomotic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bronchial anastomotic site is prone to infection by both bacterial and fungal organisms. This predisposition is probably related to immunosuppression, poor vascular supply, and impaired clearance of secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Pseudomonas and Staphylococcus aureus are the most common bacterial infections. Aspergillus colonizes the airways of approximately 20 percent of lung transplant recipients in the immediate postoperative period and may become invasive in 3 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Less common airway infections include Candida, Zygomycetes (mucormycosis), Scedosporium apiospermum, and Scedosporium prolificans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The latter two can colonize suture material and infect the anastomosis from there [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H16#H16\">",
"     \"Fungal infections following lung transplantation\", section on 'Other fungal infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients are often asymptomatic when anastomotic infection is detected at the time of surveillance bronchoscopy, although some patients have fever, cough, wheezing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemoptysis. Findings include airway erythema, pseudomembranes, ulcerations, and positive cultures of secretions. The diagnosis of invasive Aspergillus infection is based on the combination of endoscopic appearance and confirmation by histopathologic evidence of invasive Aspergillus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H8#H8\">",
"     \"Fungal infections following lung transplantation\", section on 'Tracheobronchial aspergillosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anastomotic infections appear to predispose to airway complications such as dehiscence, bronchomalacia, bronchial stenosis, and fistula formation. In one series, isolation of Aspergillus from respiratory secretions in the first 30 postoperative days was highly associated with subsequent bronchial complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of anastomotic infection includes bronchoscopic debridement of any devitalized tissue and specific antimicrobial therapy based on culture results. Aspergillus fumigatus infection is treated with a combination of systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    and inhaled amphotericin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H8#H8\">",
"     \"Fungal infections following lung transplantation\", section on 'Tracheobronchial aspergillosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Granulation tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of hyperplastic granulation tissue usually occurs within a few months of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial granulation reaction is thought to be caused by perioperative ischemia and repair. Infection, predominantly with Aspergillus, may exacerbate the growth of granulation tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H8#H8\">",
"     \"Fungal infections following lung transplantation\", section on 'Tracheobronchial aspergillosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Anastomotic infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hyperplastic granulation tissue may be asymptomatic and detected on surveillance bronchoscopy or may result in dyspnea, cough, or postobstructive pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Airflow limitation may be noted on spirometry in severe cases.",
"   </p>",
"   <p>",
"    Continued observation is reasonable, if the amount of granulation tissue does not narrow the airway substantially and symptoms are minimal. However, when granulation tissue narrows the airway by 25 percent or more, the patient is symptomatic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spirometry shows worsening airflow obstruction, the obstructing granulation tissue may be debrided via flexible bronchoscopy with laser or via rigid bronchoscopy (with forceps, cryotherapy, or laser) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38292?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Indications, contraindications, and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10453?source=see_link\">",
"     \"Bronchoscopic cryosurgery: Principles and technique\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"     \"Bronchoscopic laser resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bronchial necrosis and dehiscence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial necrosis and dehiscence range from mild, focal mucosal sloughing to extensive bronchial wall necrosis that extends more than 2 cm from the anastomosis and may be associated with partial or complete separation of the anastomosis (",
"    <a class=\"graphic graphic_table graphicRef70902 \" href=\"UTD.htm?37/34/38444\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients have some degree of anastomotic site ischemic injury and necrosis in the days following transplantation. When anastomotic dehiscence occurs, it is usually in the first or second week after transplantation. Complete bronchial dehiscence is very rare and usually follows severe primary graft dysfunction or pneumonia in the early postoperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild bronchial necrosis is asymptomatic. More severe necrosis and bronchial dehiscence may present with dyspnea, difficulty weaning from the ventilator, pneumomediastinum, subcutaneous emphysema, pneumothorax, and persistent air leak. Focal infection and peribronchial abscess may also occur. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Fistulae'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The plain chest radiograph is insensitive for detecting dehiscence; however, CT scanning can often identify dehiscence on the basis of bronchial wall defects and irregularities, mediastinal and subcutaneous air or fluid collections, pneumothorax, or poor allograft aeration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,17\">",
"     1,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchial necrosis and dehiscence are usually identified during flexible fiberoptic bronchoscopy. At the time of bronchoscopy, the degree of necrosis, presence of unraveled sutures, and evidence of focal infection are assessed. Cultures of airway secretions are obtained, if indicated (",
"    <a class=\"graphic graphic_table graphicRef70902 \" href=\"UTD.htm?37/34/38444\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of bronchial necrosis and dehiscence depends on the severity of necrosis and the presence of any associated complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the necrosis involves the mucosa, but not the bronchial wall, and no air leak is detected (Grade II, (",
"      <a class=\"graphic graphic_table graphicRef70902 \" href=\"UTD.htm?37/34/38444\">",
"       table 1",
"      </a>",
"      )), conservative management with antibiotic treatment and surveillance may suffice [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"       1",
"      </a>",
"      ]. Chest tube placement is optimized to facilitate full expansion of the transplanted lung.",
"     </li>",
"     <li>",
"      For more extensive necrosis but without bronchial anastomotic dehiscence (Grade III, (",
"      <a class=\"graphic graphic_table graphicRef70902 \" href=\"UTD.htm?37/34/38444\">",
"       table 1",
"      </a>",
"      )), some experts suggest placement of an uncovered self-expanding metallic stent (eg, Ultraflex) during flexible fiberoptic bronchoscopy, which appears to facilitate healing by stimulating neoepithelialization [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/39-42\">",
"       39-42",
"      </a>",
"      ]. These stents are usually removed after healing of the area of necrosis, which is usually about six to eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"       1",
"      </a>",
"      ]. However, our practice is to continue with conservative management rather than stent placement in order to avoid the risks associated with metallic stents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither covered metallic stents nor silicone stents have been successful in the management of bronchial necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. Silicone stents are generally avoided in this setting, as they do not promote neoepithelialization and the force required for silicone stent placement may enlarge the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link&amp;anchor=H10#H10\">",
"     \"Airway stents\", section on 'Metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with partial dehiscence, primary repair using application of fibrin glue or alpha-cyanoacrylate glue has been described in case reports, generally followed by placement of an uncovered metallic stent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/41,43\">",
"       41,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failure of the above measures and complete dehiscence are associated with high morbidity and mortality. Open surgical repair for reanastomosis, pneumonectomy, or retransplantation may be considered based on factors such as the operability of the patient, anticipated response to pneumonectomy, and availability of a new lung for retransplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fistula formation between the bronchial anastomotic site and the pleura, mediastinum, or a vascular structure is a potential consequence of bronchial anastomotic necrosis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Fistulae'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tracheobronchomalacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchomalacia is defined as a 50 percent or greater narrowing of the airway lumen during expiration; it is considered severe when the airway lumen is narrowed to 25 percent of its original area. The underlying cause is loss of integrity of the tracheal or bronchial cartilage, leading to collapsibility of the airway. Presumably, the cartilage is injured by peritransplant ischemia or infection. Tracheobronchomalacia may be seen in combination with an area of bronchial stenosis.",
"   </p>",
"   <p>",
"    Signs and symptoms of tracheobronchomalacia overlap considerably with those of bronchial stenosis and include cough, dyspnea, difficulty clearing respiratory secretions, recurrent infections, wheeze, and stridor. Spirometric flow-volume loops typically show variable obstruction worse on expiration than inspiration (",
"    <a class=\"graphic graphic_figure graphicRef77738 \" href=\"UTD.htm?18/14/18669\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnosis of tracheobronchomalacia may be suspected on the basis of clinical features and spirometric flow-volume loops, but must be confirmed bronchoscopically by visualization of airway collapse during expiration. Fiberoptic bronchoscopy is preferred over rigid bronchoscopy for optimal visualization of the dynamic reductions in airway diameter during spontaneous respiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=see_link&amp;anchor=H9#H9\">",
"     \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with possible tracheobronchomalacia, inspiratory and expiratory CT views at different levels may be helpful to visualize the extent of the area of malacia, although this technique does not replace the need for bronchoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=see_link&amp;anchor=H12#H12\">",
"     \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tracheobronchomalacia that is mild (eg, 50 to 75 percent airway collapse) and asymptomatic does not require immediate treatment, but should be observed for worsening. When symptomatic, patients can usually be managed with nocturnal noninvasive positive pressure ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When symptoms are not well-controlled with nocturnal noninvasive ventilation and 75 percent or greater occlusion of the airway due to airway collapse is observed during bronchoscopy, temporary stent(s) may be placed endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/16,40\">",
"     16,40",
"    </a>",
"    ]. In one small series of four patients with posttransplantation bronchomalacia, stent placement resulted in an 81 percent increase in forced expiratory volume in one second (FEV1) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/16\">",
"     16",
"    </a>",
"    ]. Rarely, surgical repair (tracheobronchoplasty) is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=see_link&amp;anchor=H18#H18\">",
"     \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fistulae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopleural, bronchomediastinal, and bronchovascular fistulae have all been described in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. These complications are rare, but are associated with a high morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of a bronchopleural fistula include a new or worsening pneumothorax, subcutaneous emphysema, respiratory distress, and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,46,47\">",
"     1,46,47",
"    </a>",
"    ]. Bronchomediastinal fistulae typically present with signs of mediastinal infection, such as fever, bacteremia, or a mediastinal abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A chest CT scan will usually identify pleural or mediastinal air and can be useful in guiding aspiration of mediastinal fluid collections.",
"   </p>",
"   <p>",
"    Bronchovascular fistulae may connect the bronchus with the pulmonary artery, pulmonary vein, aorta, or left atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,48,49\">",
"     1,48,49",
"    </a>",
"    ]. Patients may present with sepsis, hemoptysis, or air embolism. Risk factors for this complication include Aspergillus infection of the anastomotic site and the presence of a bronchial stent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management approach to bronchopleural, bronchomediastinal, and bronchovascular fistulae is not known, as these complications are rare. The following suggested approach is largely based on expert opinion and a few case reports.",
"   </p>",
"   <p>",
"    Bronchopleural fistulae (BPF) are treated acutely with drainage of any pleural air or empyema fluid and initiation of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients who have a small BPF (eg, 3 to 5 mm diameter) or are not candidates for surgical closure, endoscopic closure using fibrin glue may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1,46,47,50\">",
"     1,46,47,50",
"    </a>",
"    ]. Endoscopic glue closure is usually not effective for larger fistulae; these may require placement of a covered metallic stent or surgical flap closure and reinforcement, if the patient is able to tolerate a thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/50\">",
"     50",
"    </a>",
"    ]. Ventilator management of patients who have a BPF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24486?source=see_link\">",
"     \"Management of bronchopleural fistula in patients on mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of bronchomediastinal fistulae generally includes antimicrobial therapy and percutaneous drainage of any mediastinal fluid collections [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Depending on the extent of the mediastinal infection and the clinical stability of the patient, surgical debridement of the mediastinum may be indicated. Antimicrobial therapy should be broad initially and then narrowed when the sensitivities of the infecting organism are known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link&amp;anchor=H11#H11\">",
"     \"Postoperative mediastinitis after cardiac surgery\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchovascular fistulae have a high mortality rate, due to their abrupt presentation with massive hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. Successful management with lobectomy and pneumonectomy has been reported in individual cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no significant difference in overall survival in comparison with patients in whom airway complications do not develop. Moreover, airway complication is NOT a risk factor for the development of chronic rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to lung preservation, meticulous surgical technique and measures to prevent ischemia-reperfusion injury and acute rejection are important steps to prevent post-transplant airway complications. With careful management, the rate of major airway complications (dehiscence or stenosis requiring stenting) is usually less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bronchial anastomotic technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct bronchial revascularization had been proposed by some centers in an effort to lower the incidence of airway complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]; however, there is no strong evidence to support this approach and it is not widely performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lung transplantation programs use antifungal prophylaxis starting within 24 hours of transplantation, as Aspergillus airway infection is associated with an increased risk of airway complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/14,56\">",
"     14,56",
"    </a>",
"    ]. The optimal duration of antifungal prophylaxis is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Delaying use of sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    , a rapamycin derivative used to suppress transplant rejection, is associated with a markedly increased risk of airway complications when used in the first 90 days following lung transplantation. Most experts suggest delaying initiation of sirolimus until after the anastomosis is completely healed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=see_link\">",
"     \"Induction immunosuppression following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The airway anastomosis is a vulnerable site for operative complications following lung transplantation due to interruption of the bronchial artery blood supply in the transplantation process. Complications include focal infection, bronchial necrosis and dehiscence, excess granulation tissue, tracheobronchomalacia, stenosis, and fistula formation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchial stenosis may be asymptomatic and diagnosed during surveillance bronchoscopy, or it may present with dyspnea, wheezing, stridor, deteriorating pulmonary function tests, or postobstructive pneumonia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bronchial stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic anastomotic bronchial stenosis, we suggest initial dilation, rather than stent placement (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Balloon dilation may be performed via flexible or rigid bronchoscopy. Temporary stent placement is reserved for refractory stenosis, due to the relatively high complication rate associated with stents. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bronchial stenosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link\">",
"       \"Airway stents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anastomotic site infections are usually asymptomatic and diagnosed at the time of surveillance bronchoscopy. Pseudomonas and Staphylococcus aureus are the most common bacterial infections; Aspergillus infection is less common, but can lead to severe sequelae. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anastomotic infection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H8#H8\">",
"       \"Fungal infections following lung transplantation\", section on 'Tracheobronchial aspergillosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchial necrosis and dehiscence range from mild, focal mucosal sloughing to extensive bronchial wall necrosis, which may be associated with partial or complete separation of the anastomosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bronchial necrosis and dehiscence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of bronchial necrosis and dehiscence depends on the severity of necrosis and the presence of associated complications. For most patients with bronchial necrosis and dehiscence, we suggest conservative management with antibiotic treatment, maintenance of full expansion of the transplanted lung(s), and continued surveillance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative for patients with necrosis that extends beyond the mucosa is placement of an uncovered metallic stent with or without application of fibrin or cyanoacrylate glue. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete dehiscence of the anastomosis is associated with high morbidity and mortality. Open surgical repair for reanastomosis, pneumonectomy, or retransplantation may be considered based on factors such as the operability of the patient, anticipated response to pneumonectomy, and availability of a new lung for retransplantation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperplastic granulation tissue typically develops within a few months of transplantation. Symptomatic patients may have dyspnea, cough, or postobstructive pneumonia. When the granulation tissue narrows the airway by 25 percent or more, we suggest debridement via fiberoptic or rigid bronchoscopy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Forceps, cryotherapy, or laser may be used to clear the granulation tissue. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Granulation tissue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tracheobronchomalacia is defined as a 50 percent or greater narrowing of the airway lumen during expiration, confirmed bronchoscopically. Asymptomatic airway collapse does not require treatment. For mild degrees of airway collapse (eg, 50 to 75 percent) associated with symptoms, we suggest supportive care with nocturnal noninvasive positive pressure ventilation, rather than stent placement (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When airway collapse is greater than 75 percent, nocturnal noninvasive positive pressure ventilation is less likely to be adequate to control symptoms. In these patients, we suggest placement of a temporary stent or surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Tracheobronchomalacia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchopleural, bronchomediastinal, and bronchovascular fistulae are rare complications of lung transplantation. Treatment of bronchopleural fistulae includes acute drainage of pleural air or empyema fluid and antibiotic therapy, as fistulae are highly associated with anastomotic infection. Treatment of bronchomediastinal fistulae includes percutaneous drainage of any mediastinal abscess collection and antibiotic therapy. A variety of methods have been tried to close the bronchial orifice of fistulae including surgery, application of fibrin glue, and placement of a covered metallic stent. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Fistulae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/1\">",
"      Santacruz JF, Mehta AC. Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis. Proc Am Thorac Soc 2009; 6:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/2\">",
"      Shennib H, Massard G. Airway complications in lung transplantation. Ann Thorac Surg 1994; 57:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/3\">",
"      Van De Wauwer C, Van Raemdonck D, Verleden GM, et al. Risk factors for airway complications within the first year after lung transplantation. Eur J Cardiothorac Surg 2007; 31:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/4\">",
"      Meyers BF, de la Morena M, Sweet SC, et al. Primary graft dysfunction and other selected complications of lung transplantation: A single-center experience of 983 patients. J Thorac Cardiovasc Surg 2005; 129:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/5\">",
"      Barman SA, Ardell JL, Parker JC, et al. Pulmonary and systemic blood flow contributions to upper airways in canine lung. Am J Physiol 1988; 255:H1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/6\">",
"      Dhillon GS, Zamora MR, Roos JE, et al. Lung transplant airway hypoxia: a diathesis to fibrosis? Am J Respir Crit Care Med 2010; 182:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/7\">",
"      Pinsker KL, Koerner SK, Kamholz SL, et al. Effect of donor bronchial length on healing: a canine model to evaluate bronchial anastomotic problems in lung transplantation. J Thorac Cardiovasc Surg 1979; 77:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/8\">",
"      Cooper JD, Pearson FG, Patterson GA, et al. Technique of successful lung transplantation in humans. J Thorac Cardiovasc Surg 1987; 93:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/9\">",
"      Griffith BP, Magee MJ, Gonzalez IF, et al. Anastomotic pitfalls in lung transplantation. J Thorac Cardiovasc Surg 1994; 107:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/10\">",
"      Date H, Trulock EP, Arcidi JM, et al. Improved airway healing after lung transplantation. An analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg 1995; 110:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/11\">",
"      Calhoon JH, Grover FL, Gibbons WJ, et al. Single lung transplantation. Alternative indications and technique. J Thorac Cardiovasc Surg 1991; 101:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/12\">",
"      Choong CK, Sweet SC, Zoole JB, et al. Bronchial airway anastomotic complications after pediatric lung transplantation: incidence, cause, management, and outcome. J Thorac Cardiovasc Surg 2006; 131:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/13\">",
"      Ruttmann E, Ulmer H, Marchese M, et al. Evaluation of factors damaging the bronchial wall in lung transplantation. J Heart Lung Transplant 2005; 24:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/14\">",
"      Herrera JM, McNeil KD, Higgins RS, et al. Airway complications after lung transplantation: treatment and long-term outcome. Ann Thorac Surg 2001; 71:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/15\">",
"      Alvarez A, Algar J, Santos F, et al. Airway complications after lung transplantation: a review of 151 anastomoses. Eur J Cardiothorac Surg 2001; 19:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/16\">",
"      Chhajed PN, Malouf MA, Tamm M, et al. Interventional bronchoscopy for the management of airway complications following lung transplantation. Chest 2001; 120:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/17\">",
"      Shitrit D, Valdsislav P, Grubstein A, et al. Accuracy of virtual bronchoscopy for grading tracheobronchial stenosis: correlation with pulmonary function test and fiberoptic bronchoscopy. Chest 2005; 128:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/18\">",
"      Hasegawa T, Iacono AT, Orons PD, Yousem SA. Segmental nonanastomotic bronchial stenosis after lung transplantation. Ann Thorac Surg 2000; 69:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/19\">",
"      Moreno P, Alvarez A, Algar FJ, et al. Incidence, management and clinical outcomes of patients with airway complications following lung transplantation. Eur J Cardiothorac Surg 2008; 34:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/20\">",
"      Thistlethwaite PA, Yung G, Kemp A, et al. Airway stenoses after lung transplantation: incidence, management, and outcome. J Thorac Cardiovasc Surg 2008; 136:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/21\">",
"      Sch&auml;fers HJ, Sch&auml;fer CM, Zink C, et al. Surgical treatment of airway complications after lung transplantation. J Thorac Cardiovasc Surg 1994; 107:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/22\">",
"      Marulli G, Loy M, Rizzardi G, et al. Surgical treatment of posttransplant bronchial stenoses: case reports. Transplant Proc 2007; 39:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/23\">",
"      Murthy SC, Blackstone EH, Gildea TR, et al. Impact of anastomotic airway complications after lung transplantation. Ann Thorac Surg 2007; 84:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/24\">",
"      De Gracia J, Culebras M, Alvarez A, et al. Bronchoscopic balloon dilatation in the management of bronchial stenosis following lung transplantation. Respir Med 2007; 101:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/25\">",
"      Mayse ML, Greenheck J, Friedman M, Kovitz KL. Successful bronchoscopic balloon dilation of nonmalignant tracheobronchial obstruction without fluoroscopy. Chest 2004; 126:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/26\">",
"      Bolliger CT, Sutedja TG, Strausz J, Freitag L. Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. Eur Respir J 2006; 27:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/27\">",
"      Murgu SD, Colt HG. Complications of silicone stent insertion in patients with expiratory central airway collapse. Ann Thorac Surg 2007; 84:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/28\">",
"      Dutau H, Cavailles A, Sakr L, et al. A retrospective study of silicone stent placement for management of anastomotic airway complications in lung transplant recipients: short- and long-term outcomes. J Heart Lung Transplant 2010; 29:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/29\">",
"      Gildea TR, Murthy SC, Sahoo D, et al. Performance of a self-expanding silicone stent in palliation of benign airway conditions. Chest 2006; 130:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/30\">",
"      Sundset A, Lund MB, Hansen G, et al. Airway complications after lung transplantation: long-term outcome of silicone stenting. Respiration 2012; 83:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/31\">",
"      Fernandez-Bussy S, Akindipe O, Kulkarni V, et al. Clinical experience with a new removable tracheobronchial stent in the management of airway complications after lung transplantation. J Heart Lung Transplant 2009; 28:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/32\">",
"      Gottlieb J, Fuehner T, Dierich M, et al. Are metallic stents really safe? A long-term analysis in lung transplant recipients. Eur Respir J 2009; 34:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/33\">",
"      Camargo Jde J, Camargo SM, Machuca TN, et al. Surgical maneuvers for the management of bronchial complications in lung transplantation. Eur J Cardiothorac Surg 2008; 34:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/34\">",
"      Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/35\">",
"      Mehrad B, Paciocco G, Martinez FJ, et al. Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 2001; 119:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/36\">",
"      Silveira FP, Kwak EJ, Paterson DL, et al. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant 2008; 27:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/37\">",
"      McGuire FR, Grinnan DC, Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant 2007; 26:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/38\">",
"      Shah, SS, Karnak, D, Budev, M, et al. Endobronchial Pseudallescheria boydii in lung transplant patient with cystic fibrosis. J Bronchol 2007; 14:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/39\">",
"      Chhajed PN, Tamm M. Uncovered metallic stents for anastomotic dehiscence after lung transplantation. J Heart Lung Transplant 2005; 24:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/40\">",
"      Kapoor BS, May B, Panu N, et al. Endobronchial stent placement for the management of airway complications after lung transplantation. J Vasc Interv Radiol 2007; 18:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/41\">",
"      Mughal MM, Gildea TR, Murthy S, et al. Short-term deployment of self-expanding metallic stents facilitates healing of bronchial dehiscence. Am J Respir Crit Care Med 2005; 172:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/42\">",
"      Ferraroli GM, Ravini M, Torre M, et al. Successful treatment of bronchial dehiscence with endobronchial stent in lung transplantation. Diagn Ther Endosc 2000; 6:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/43\">",
"      Maloney JD, Weigel TL, Love RB. Endoscopic repair of bronchial dehiscence after lung transplantation. Ann Thorac Surg 2001; 72:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/44\">",
"      Novick RJ, Kaye MP, Patterson GA, et al. Redo lung transplantation: a North American-European experience. J Heart Lung Transplant 1993; 12:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/45\">",
"      Strueber M, Fischer S, Gottlieb J, et al. Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg 2006; 132:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/46\">",
"      Chang CC, Hsu HH, Kuo SW, Lee YC. Bronchoscopic gluing for post-lung-transplant bronchopleural fistula. Eur J Cardiothorac Surg 2007; 31:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/47\">",
"      Mora G, de Pablo A, Garc&iacute;a-Gallo CL, et al. [Is endoscopic treatment of bronchopleural fistula useful?]. Arch Bronconeumol 2006; 42:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/48\">",
"      Hoff SJ, Johnson JE, Frist WH. Aortobronchial fistula after unilateral lung transplantation. Ann Thorac Surg 1993; 56:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/49\">",
"      Johnston SL, Halabi S, Cohoon K, et al. Stroke and myocardial infarction as late complications of lung transplantation. J Heart Lung Transplant 2007; 26:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/50\">",
"      Lois M, Noppen M. Bronchopleural fistulas: an overview of the problem with special focus on endoscopic management. Chest 2005; 128:3955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/51\">",
"      Rea F, Marulli G, Loy M, et al. Salvage right pneumonectomy in a patient with bronchial-pulmonary artery fistula after bilateral sequential lung transplantation. J Heart Lung Transplant 2006; 25:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/52\">",
"      Guth S, Mayer E, Fischer B, et al. Bilobectomy for massive hemoptysis after bilateral lung transplantation. J Thorac Cardiovasc Surg 2001; 121:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/53\">",
"      Weder W, Inci I, Korom S, et al. Airway complications after lung transplantation: risk factors, prevention and outcome. Eur J Cardiothorac Surg 2009; 35:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/54\">",
"      Kamler M, Nowak K, Bock M, et al. Bronchial artery revascularization restores peribronchial tissue oxygenation after lung transplantation. J Heart Lung Transplant 2004; 23:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/55\">",
"      Nowak K, Kamler M, Bock M, et al. Bronchial artery revascularization affects graft recovery after lung transplantation. Am J Respir Crit Care Med 2002; 165:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26121/abstract/56\">",
"      Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004; 23:1376.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4662 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26121=[""].join("\n");
var outline_f25_32_26121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AIRWAY SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPECIFIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bronchial stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vanishing bronchus intermedius",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anastomotic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Granulation tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bronchial necrosis and dehiscence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tracheobronchomalacia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fistulae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bronchial anastomotic technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Delaying use of sirolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4662|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/14/18669\" title=\"figure 1\">",
"      Tracheomalacia FV loop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/34/38444\" title=\"table 1\">",
"      Airway complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38292?source=related_link\">",
"      Bronchoscopic cryosurgery: Indications, contraindications, and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10453?source=related_link\">",
"      Bronchoscopic cryosurgery: Principles and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27126?source=related_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3688?source=related_link\">",
"      Induction immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24486?source=related_link\">",
"      Management of bronchopleural fistula in patients on mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12233?source=related_link\">",
"      Noninfectious complications following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/50/17194?source=related_link\">",
"      Physiologic changes following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18088?source=related_link\">",
"      Tracheomalacia and tracheobronchomalacia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26122="Treatment of lipids (including hypercholesterolemia) in secondary prevention";
var content_f25_32_26122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26122/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26122/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/32/26122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/32/26122/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/32/26122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known coronary heart disease (CHD) or coronary equivalents (as defined below) are at high risk for cardiovascular events. Statins have been shown to reduce such events, and to reduce all-cause mortality. Trials of other lipid-lowering agents have also shown reductions in cardiovascular events.",
"   </p>",
"   <p>",
"    The major issues related to the treatment of different causes of hypercholesterolemia for secondary prevention of coronary heart disease are reviewed here, as are the medications available for treatment.",
"   </p>",
"   <p>",
"    The clinical trials upon which the recommendations are based are discussed in detail separately as is treatment in primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also discussed separately is a discussion of the appropriate intensity of lipid lowering therapy in secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF PATIENTS AT RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally suggest following the Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). The ATP III recommendations for the treatment of hypercholesterolemia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of patients with known CHD or a CHD risk equivalent will require lipid lowering therapy to meet ATP III goals. Additionally, as discussed below, we suggest that all such patients be treated with statin therapy when tolerated. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Summary and recommendations'",
"    </a>",
"    below.) CHD equivalents, that is, risk factors that place the patient at similar risk for CHD events as a history of CHD itself, include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Many patients with diabetes mellitus (see",
"      <a class=\"local\" href=\"#H1033672373\">",
"       'Diabetes mellitus as a CHD equivalent'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Multiple risk factors that confer a 10-year risk of CHD &gt;20 percent using the ATP III modification of the Framingham risk tables (",
"      <a class=\"graphic graphic_table graphicRef64978 graphicRef76742 \" href=\"UTD.htm?30/1/30751\">",
"       table 1A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the conditions identified by ATP III as CHD equivalents, we consider chronic renal insufficiency (defined by a plasma creatinine concentration that exceeds 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or an estimated glomerular filtration rate that is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) to be a CHD equivalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Chronic kidney disease as an independent risk factor for CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1033672373\">",
"    <span class=\"h2\">",
"     Diabetes mellitus as a CHD equivalent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ATP III considered diabetes mellitus (DM) to be a CHD risk equivalent (risk of CHD events greater than 20 percent in 10 years) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    ), this actually averages events across patients with widely differing risks of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Issues that may affect risk with DM include patient age, sex, other cardiovascular risk factors, duration of DM, and whether the patient has type 1 or type 2 DM.",
"   </p>",
"   <p>",
"    Given this, it would be preferable to calculate patient-specific risks rather than to simply consider all patients with DM to have a CHD risk equivalent, particularly in patients who are under age 60 without multiple cardiovascular risk factors. A downloadable calculator for this purpose is available for patients with type 2 DM from the",
"    <a class=\"external\" href=\"file://www.dtu.ox.ac.uk/riskengine/\">",
"     UK Prospective Diabetes Study",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If a patient-specific risk calculator cannot be accessed, we suggest considering the following patients with diabetes mellitus (DM) to have a CHD risk equivalent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men over age 40 with type 2 DM and any other CHD risk factor, or over age&nbsp;50 with or without other CHD risk factors",
"     </li>",
"     <li>",
"      Women over age 45 with type 2 DM and any other CHD risk factor, or over age&nbsp;55 with or without other CHD risk factors",
"     </li>",
"     <li>",
"      Men or women of any age who have had DM (type 1 or type 2) for more than 20 years if they have another risk factor or more than 25 years without another risk factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular benefits of cholesterol lowering with statin drugs have been demonstrated in various groups including [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with CHD, with or without hyperlipidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Men with hyperlipidemia but no known CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Men with hypertension and multiple cardiac risk factors but without hyperlipidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Men and women with average total and LDL-C levels and no known CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative risk reduction in cardiovascular outcomes for each of these studies was similar. However, many more patients need to be treated to achieve benefit for primary compared with secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/10\">",
"     10",
"    </a>",
"    ]. As an example, the number needed to treat for one year to prevent one fatal or nonfatal coronary event (not counting uncomplicated coronary interventions) varies from 63 in 4S (patients with CHD and hyperlipidemia) and 71 in ASCOT-LLA (patients with hypertension plus at least three other cardiac risk factors, but without hyperlipidemia) to 256 in",
"    <span class=\"nowrap\">",
"     AFCAPS/TexCAPS",
"    </span>",
"    (patients without CHD or hyperlipidemia). The number needed to treat was intermediate in WOSCOPS (217) and CARE (167), patients with hyperlipidemia and no CHD, and patients with CHD and normal lipids, respectively.",
"   </p>",
"   <p>",
"    The statins are the only class of drugs to demonstrate clear improvements in overall mortality in primary and secondary prevention; follow-up from a clinical trial of niacin suggested some mortality benefits in secondary prevention. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Drug therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current ATP guidelines for LDL-C lowering in patients with existing CHD are more aggressive than those issued previously. This reflects a better understanding of both the high risk conferred by the presence of CHD and the impact of cholesterol lowering in these patients. Men and women with CHD have a risk of myocardial infarction",
"    <strong>",
"     20 times higher",
"    </strong>",
"    than those without CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large trials have demonstrated that lipid lowering is beneficial in patients with CHD. A meta-analysis of 34 trials that looked at the use of statins and other therapies to reduce cholesterol levels in approximately 25,000 subjects with CHD found that cholesterol lowering therapy was associated with a 13 percent reduction in mortality risk but no change in noncardiovascular deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of 25 trials using statins for cholesterol lowering in 69,511 patients with CHD found a 16 percent reduction in the risk of all-cause mortality (relative risk 0.84, 95% CI 0.79-0.89) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific results from some of the trials of statins include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Scandinavian",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      Survival Study (4S) of patients with hyperlipidemia (baseline plasma total cholesterol levels between 212 and 309",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.5 and 8.0",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      found that simvastatin therapy versus placebo for 5.4 years resulted in statistically significant reductions in total mortality (8 versus 12 percent), major coronary events (19 versus 28 percent), CHD deaths (42 percent reduction), revascularization procedures (CABG or coronary angioplasty, 37 percent reduction), and fatal plus nonfatal cerebrovascular events (2.7 versus 4.3 percent) (",
"      <a class=\"graphic graphic_figure graphicRef72721 \" href=\"UTD.htm?24/34/25134\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81991 \" href=\"UTD.htm?18/55/19325\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CARE trial treated patients with average cholesterol levels (mean serum total cholesterol concentration of 209",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [5.4",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      (40 mg before sleep) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/6\">",
"       6",
"      </a>",
"      ]. At five years, benefits with pravastatin compared with placebo included significant reductions in the combined incidence of coronary death and nonfatal MI (10.2 versus 13.2 percent, p = 0.003), (",
"      <a class=\"graphic graphic_figure graphicRef82485 \" href=\"UTD.htm?23/30/24045\">",
"       figure 3",
"      </a>",
"      ), the need for revascularization (14.1 versus 18.8 percent, p&lt;0.001), and the frequency of stroke (2.6 versus 3.8 percent, p = 0.03). The benefits were more apparent among women, older patients (above age 60), and pretreatment serum LDL-C above 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      More recently, the Heart Protection Study randomly assigned 20,536 subjects to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo: 33 percent had baseline LDL-C &lt;116",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      25 percent had a level of 116 to 135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3 to 3.5",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and 42 percent had levels &gt;135",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/14\">",
"       14",
"      </a>",
"      ]. Entry criteria included a history of cardiovascular disease (coronary cerebrovascular or peripheral vascular disease), diabetes mellitus, or treated hypertension. Thus, most patients were treated for secondary prevention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H28#H28\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Heart Protection Study'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      After an average follow-up of 5.5 years, there were significant reductions in all-cause mortality (12.9 versus 14.7 percent; relative risk reduction [RRR] 13 percent), deaths from heart disease or related blood vessel disease (7.6 versus 9.1 percent; RRR 17 percent), and major cardiovascular events (19.8 versus 25.2 percent; RRR 24 percent) (",
"      <a class=\"graphic graphic_figure graphicRef81866 \" href=\"UTD.htm?13/44/14030\">",
"       figure 4",
"      </a>",
"      ). The percent reduction in events was",
"      <strong>",
"       similar",
"      </strong>",
"      in the three tertiles of baseline LDL-C (the lowest being &lt;116",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [&lt;3",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and was also similar in those with a baseline LDL-C below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"       <br/>",
"       <br/>",
"       These",
"      </span>",
"      subgroup observations suggest that if there is a threshold below which lowering LDL-C no longer reduces cardiovascular risk in patients with cardiovascular disease, it is apparently at a much lower concentration than is typically seen in Western populations. The benefit in patients with lower LDL-C concentrations may reflect actions of statins other than lipid lowering. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Summary and recommendations'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"       \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the reduction in clinical events, serial angiographic studies have shown that cholesterol lowering can retard the progression, and in some cases, induce regression of coronary atherosclerosis (",
"    <a class=\"graphic graphic_table graphicRef64360 \" href=\"UTD.htm?0/20/333\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/15\">",
"     15",
"    </a>",
"    ]. This benefit is most prominent when LDL-C levels are reduced below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or lower. In general, lipid-lowering drugs are required, since dietary modification alone is relatively ineffective (",
"    <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"     table 3",
"    </a>",
"    ). A complete review of these issues is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary intervention trials have shown that, compared with men, women may have increased regression of coronary lesions and a similar improvement in survival with intensive lipid lowering [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=see_link\">",
"     \"Determinants and management of cardiovascular risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, these findings suggest that patients who already have CHD merit aggressive lipid management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intensity of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate goal LDL-C in patients with CHD or CHD equivalents being treated for secondary prevention is controversial and is discussed in additional detail separately. We suggest the following management (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with CHD or a CHD equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"       table 4",
"      </a>",
"      ) who can tolerate statin therapy, we suggest treatment with at least a moderate dose of a statin (eg, 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , or 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      )",
"      <strong>",
"       independent of the baseline LDL-C",
"      </strong>",
"      . That is, even if a patient&rsquo;s baseline LDL-C is below goal or is close to goal such that a low dose of a statin would be expected to reduce the LDL-C below the ATP-III goal, we would initiate a statin and choose a moderate dose of a statin. The below goal-based recommendations assume that patients with CHD or a CHD equivalent will be treated with at least a moderate dose of a statin.",
"     </li>",
"     <li>",
"      Intensive statin therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily reduces mortality in patients with an acute coronary syndrome and is recommended as initial therapy. Given that benefit occurs earlier than the first cholesterol measurement on therapy would normally be obtained, we recommend that patients be started on atorvastatin 80 mg daily early in their hospital course, rather than titrating the dose upward in the outpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"       \"Cholesterol lowering after an acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients at very high risk for CHD events such as those in the proposed NCEP guidelines (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 3",
"      </a>",
"      ) might also be expected to benefit from more intensive lipid lowering therapy. We suggest that such patients be treated with a dose of a statin that reduces their LDL-C at least below 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      If such patients cannot achieve an LDL-C below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with a statin alone, we suggest the addition of a second lipid-lowering agent. Other experts, including other authors for UpToDate, would make differing recommendations regarding the need for a second agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the increased side effects with more intensive statin therapy, and the lack of benefit on all-cause mortality, we suggest that, except in the highest risk patients (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 3",
"      </a>",
"      ), patients with stable CHD or a CHD equivalent be treated with a dose of statin that reduces the LDL-C to less than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      However, more aggressive LDL-C lowering treatment to slightly reduce nonfatal cardiovascular events is a reasonable option in patients for whom the additional therapy would not impose undue burdens from side effects or cost. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H10#H10\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Putting the evidence together'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of clear evidence, we suggest that patients with stable CHD who do not tolerate a statin be treated with another lipid-lowering agent. Although the evidence also does not allow a clear answer on whether to add a second agent in usual risk patients with stable CHD who are unable to achieve their goal LDL-C with a statin alone, we suggest the use of a second agent in such patients. Other experts, including other authors for UpToDate, would make differing recommendations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264877640\">",
"    <span class=\"h3\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in the prior section, we suggest initiation of moderate statin therapy in all patients with CHD or a CHD risk equivalent. If, instead, a decision is made to target a particular LDL-C goal, we feel that drug therapy should not be postponed if the target for LDL-C lowering is unlikely to be achieved in the near term by nonpharmaceutical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/18\">",
"     18",
"    </a>",
"    ]. A proposal from the Coordinating Committee of the National Cholesterol Education Program (NCEP) makes a similar recommendation to initiate drug therapy at the same time as lifestyle changes whenever the LDL-C is &ge;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/19\">",
"     19",
"    </a>",
"    ]. The statin dose should be titrated every four to six weeks to achieve the goal.",
"   </p>",
"   <p>",
"    Patients with an acute myocardial infarction should be started on a statin during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of lipid disorders in primary prevention is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cost-effectiveness of cholesterol-lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of cholesterol lowering has been evaluated for secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 4S study estimated the cost savings derived from cholesterol lowering using a cost-minimization analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/16,22\">",
"       16,22",
"      </a>",
"      ]. Cost minimization analyses approximate health costs in the two treated groups and attribute the difference in costs to the alternate therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/16\">",
"       16",
"      </a>",
"      ]. Hospitalizations from acute cardiac events (myocardial infarction, angina pectoris, congestive heart failure) were reduced by 32 percent and revascularization procedures by 26 percent in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      . The mean length of stay for acute cardiovascular events and revascularization procedures was also less in the simvastatin group (7.1 versus 7.9 days, p = 0.006). The estimated reduction in costs over 5.4 years with simvastatin therapy would be $3872 per patient. However, the cost of the medication used is higher in the United States.",
"     </li>",
"     <li>",
"      A second report from the 4S study analyzed the cost-effectiveness of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      in relation to age, sex, and cholesterol level using Swedish healthcare prices [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/22\">",
"       22",
"      </a>",
"      ]. When the analysis included indirect costs associated with decreased morbidity from CHD, treatment led to a savings among men and women aged 35; the cost per year of life gained ranged from $1,200 to $13,300 in older patients.",
"     </li>",
"     <li>",
"      Another cost-effectiveness analysis of secondary prevention was based upon the CARE trial in which patients had only",
"      <strong>",
"       borderline elevations",
"      </strong>",
"      in serum cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/23\">",
"       23",
"      </a>",
"      ]. In this lower-risk group,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      therapy was associated with an incremental cost of $16,000 to $32,000 per quality-adjusted life-year gained; cost-effectiveness was greater for patients more than 60 years of age or with pretreatment LDL-C above 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These studies, published between 1996 and 2001, show that treatment with statins for secondary prevention was cost-effective for secondary prevention even in an era when statins were more expensive. Cost-effectiveness will have improved as the cost of such therapy has come down. The cost-effectiveness of statins in primary prevention is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Cost-effectiveness modeling'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Safety of cholesterol lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some initial studies, such as the Helsinki Heart Study, suggested that cholesterol lowering might be associated with an increased incidence of noncardiovascular deaths due to accidents, suicide, or violence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/24\">",
"     24",
"    </a>",
"    ]. However, more recent larger trials (primarily conducted with an HMG CoA reductase inhibitor [statin]) have been unable to confirm such a relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/14,25-27\">",
"     14,25-27",
"    </a>",
"    ]. A meta-analysis of 19 randomized trials of primary and secondary prevention found no increase in noncardiovascular mortality associated with cholesterol-lowering therapy overall or with the administration of a statin; there may be a modest increase in risk with nonstatin therapy (p = 0.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/27\">",
"     27",
"    </a>",
"    ]. There have been case reports of patients developing severe irritability and aggression associated with the use of statins [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/28\">",
"     28",
"    </a>",
"    ]. It is not known whether the statin use caused these symptoms, but very rare idiosyncratic reactions of this sort could be missed in controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Specific groups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment in diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, diabetes mellitus is considered a CHD equivalent (",
"    <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"     table 4",
"    </a>",
"    ) and, as mentioned above, both the CARE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/29\">",
"     29",
"    </a>",
"    ] and the Heart Protection Study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/14,30\">",
"     14,30",
"    </a>",
"    ] found significant improvement in outcomes with statin therapy even at LDL-cholesterol (LDL-C) values below 116",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.0",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The CARDS study found similar benefits of statin therapy in patients with an LDL-C above or below 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/31\">",
"     31",
"    </a>",
"    ]. A meta-analysis of patients with diabetes in 14 randomized trials of statins (n = 18,686) also found that relative benefits appeared unrelated to the baseline LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the ATP-III goal LDL-C is similar to that in patients with CHD: less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    As discussed above, even more aggressive target LDL-C goals of 70 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8 to 2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may be appropriate in some patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Intensity of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treatment in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether to treat hypercholesterolemia in an older individual is highly individualized, based upon both chronological and physiologic age. A patient with a limited life span from a concomitant illness is probably not a candidate for drug therapy. On the other hand, an otherwise healthy older individual should not be denied drug therapy simply on the basis of age alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be ample evidence supporting the use of lipid-lowering therapy for",
"    <strong>",
"     secondary prevention",
"    </strong>",
"    in older patients with established CHD who do not have life-limiting comorbid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"     1",
"    </a>",
"    ]. In the CARE trial, for example, approximately one-half of patients were above age 60, and the benefit of cholesterol lowering in these patients was similar to that in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, the percent reduction in events in the Heart Protection Study was similar in patients above and below age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=see_link\">",
"     \"Treatment of dyslipidemia in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment in patients with familial hypercholesterolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to patients with either homozygous or heterozygous familial hypercholesterolemia (FH) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link&amp;anchor=H3#H3\">",
"     \"Diseases associated with atherosclerosis in childhood\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Patients with low HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy aimed at raising HDL-C levels into the normal range has been advocated by some investigators in patients with",
"    <strong>",
"     overt CHD",
"    </strong>",
"    and those at high risk because of a",
"    <strong>",
"     strong family history",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In ATP III, low HDL-C is defined as &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.03",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    a change from the level of 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.91",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in ATP II [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"     1",
"    </a>",
"    ]. The details of medical therapy for patients with low HDL-C are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Patients with hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be beneficial to treat hypertriglyceridemia in patients who also have hypercholesterolemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoalphalipoproteinemia. Since triglyceride-rich lipoproteins also transport cholesterol, hypercholesterolemia of varying severity often accompanies hypertriglyceridemia. The magnitude of the hypercholesterolemia depends upon the number and composition of triglyceride-rich lipoproteins that are present. Thus, the presence of hypertriglyceridemia should suggest that any increase in serum total cholesterol is due, at least in part, to increased VLDL-cholesterol.",
"   </p>",
"   <p>",
"    Possible indications for treatment of",
"    <strong>",
"     isolated",
"    </strong>",
"    hypertriglyceridemia include overt CHD, a strong family history of CHD, and multiple coexisting cardiac risk factors. In addition, subjects with very high triglyceride levels (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    should be treated to avoid pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As mentioned above, ATP III identifies the non-HDL-C concentration as a secondary target of therapy in people who have high triglycerides (&ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.26",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"     1",
"    </a>",
"    ]. The goal for non-HDL-C in this circumstance is a concentration that is 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.78",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    higher than that for LDL-C (",
"    <a class=\"graphic graphic_table graphicRef53318 \" href=\"UTD.htm?2/46/2795\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of C-reactive protein (CRP) appear to be associated with clinical outcomes. The possible implications of this for identifying appropriate patients for lipid lowering therapy and for goals of therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1480759365\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid lowering therapy, at least with statins, is effective in patients with cerebrovascular disease. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heart failure do not appear to gain significant benefits from statins, even when they have ischemic causes of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=see_link\">",
"     \"Statin therapy in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on dialysis do not appear to gain significant benefits from statin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .) This does not change the recommendation that people with chronic kidney disease who do not yet require dialysis be aggressively treated as having a coronary risk equivalent when choosing statin therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Identification of patients at risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611789608\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised that the evidence for a benefit for treating women for secondary prevention with statins is not as convincing as the evidence in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/35\">",
"     35",
"    </a>",
"    ]. A 2012 meta-analysis of randomized trials concluded that while statins prevent CV events in both men and women, they are not beneficial in reducing stroke or all-cause mortality in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/36\">",
"     36",
"    </a>",
"    ]. Others have raised objections to this and similar analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/37\">",
"     37",
"    </a>",
"    ]. A particular concern is that, in general, the default assumption should be that relative effects across subgroups (such as men and women) are similar and an absence of a statistically-significant effect in a particular subgroup should not be a reason to conclude that real differences exist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this 2012 meta-analysis, there was no statistically-significant difference between the relative effects of statins in men and women on the outcomes of stroke or all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/36\">",
"     36",
"    </a>",
"    ]. We believe the best evidence suggests that statins are similarly effective, in terms of",
"    <strong>",
"     relative effect",
"    </strong>",
"    , for secondary prevention of the same CV outcomes in both men and women. Men and women frequently have different baseline risks of specific CV outcomes, and the expected",
"    <strong>",
"     absolute benefit",
"    </strong>",
"    of statin therapy depends on the baseline risk in an individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with high LDL-C should undergo lifestyle modifications in an effort to reduce the serum cholesterol. Many will not reach the goal level of cholesterol with these measures and will require drug therapy. The goals of cholesterol lowering are described above in the sections on primary and secondary prevention. The following section will review how these goals can be achieved. A number of issues arise when treating patients with specific primary and secondary disorders of LDL metabolism. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with high LDL-C should undergo lifestyle modifications (therapeutic lifestyle changes as stated in ATP III) such as reductions in dietary total and saturated fat (",
"    <a class=\"graphic graphic_table graphicRef78862 \" href=\"UTD.htm?40/16/41227\">",
"     table 6",
"    </a>",
"    ), weight loss in overweight patients, aerobic exercise, and eating a diet rich in fruits and vegetables. The United Kingdom Lipid Clinics Program of 2508 subjects found that, with diet alone, 60 percent of subjects had a mean reduction in body weight of 1.8 percent, which was associated with 5 to 7 percent reductions in serum total and LDL-C [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/39\">",
"     39",
"    </a>",
"    ]. Other diets can lower LDL-C by as much as 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another study randomly assigned 180 postmenopausal women and 197 men with low levels of HDL-C and moderately elevated levels of LDL-C to aerobic exercise, diet, diet plus exercise, or no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/41\">",
"     41",
"    </a>",
"    ]. Although there were no significant changes in HDL-C in any group, there were significant reductions in LDL-C in both men and women (14.5 and 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.38 and 0.52",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively) in the diet plus exercise group compared with control or diet alone and, in men, in the diet plus exercise group compared with exercise alone.",
"   </p>",
"   <p>",
"    The benefits of LDL-C lowering may be evident within six to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The individual response to a cholesterol-lowering diet depends upon many factors; some of the response is genetically determined, and increased body mass index is associated with less response to dietary change [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients who are referred to a dietitian may have greater success in the short term with lowering LDL-C compared with patients who receive dietary counseling by physicians, although long-term compliance with dietary therapy is inadequate for both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. As a result, there should be no hesitation in beginning a hypolipidemic drug regimen in patients who fulfill the criteria described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-altering agents encompass several classes of drugs that include statins, fibric acid derivatives, bile acid sequestrants, nicotinic acid, and cholesterol absorption inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    ). These drugs differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular drug are influenced by the underlying lipid abnormality. Conventional dosing regimens and common adverse reactions are described in a table (",
"    <a class=\"graphic graphic_table graphicRef77498 \" href=\"UTD.htm?28/1/28701\">",
"     table 7",
"    </a>",
"    ), and the range of expected changes in the lipid profile are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"UTD.htm?21/47/22268\">",
"     table 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The statins are the only class of drugs to demonstrate clear improvements in overall mortality in primary and secondary prevention; follow-up from a clinical trial of niacin suggested some mortality benefits in secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/47\">",
"     47",
"    </a>",
"    ]. Large trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , clofibrate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    in primary prevention not only failed to show mortality benefits but showed worrisome trends toward an increase in noncardiac deaths. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .) A large trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    in patients with diabetes (some of whom had known cardiovascular disease) found a nonsignificant increase in overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/48\">",
"     48",
"    </a>",
"    ]. A large trial of gemfibrozil in secondary prevention also failed to show any improvement in overall mortality, although cardiac mortality was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H42#H42\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'VA-HIT trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'FIELD trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As such, statins are the first choice in virtually all patients with hypercholesterolemia in whom the goal is reduction of primary or secondary cardiovascular risk. If goal LDL-C levels cannot be attained with the use of a statin alone, it is uncertain whether the addition of other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    provides additional clinical benefit, even though LDL-C levels can be reduced further. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended goal LDL-C concentrations are described above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effects of therapy'",
"    </a>",
"    above.) If an additional agent is needed, abnormalities in other lipoproteins may influence the choice of that agent. In patients with a pure elevation in LDL-C who are being treated for secondary prevention, addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    or a bile acid sequestrant is a reasonable option.",
"   </p>",
"   <p>",
"    In patients who do not tolerate a statin because of myopathy, it may be appropriate to try another statin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    that appears to have a lower risk of producing myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who do not tolerate any statin and are being treated for secondary prevention, reasonable options include the use of bile acid sequestrants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    , niacin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    . Referral to a lipid specialist is appropriate in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The statins are the most commonly used drugs in the treatment of hypercholesterolemia. They are the most powerful drugs for lowering LDL-C, with reductions in the range of 20 to 60 percent (",
"    <a class=\"graphic graphic_table graphicRef53730 \" href=\"UTD.htm?14/30/14829\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     Fluvastatin",
"    </a>",
"    is somewhat less potent, decreasing LDL-C levels by 20 to 25 percent at the maximum recommended dose [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     Atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    are the most potent statins approved in the United States, reducing LDL-C levels by around 60 percent at doses of 80 and 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively (",
"    <a class=\"graphic graphic_figure graphicRef60663 \" href=\"UTD.htm?6/34/6703\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/54\">",
"     54",
"    </a>",
"    ]. An additional benefit of atorvastatin and rosuvastatin is more effective triglyceride lowering in patients with hypercholesterolemia; triglyceride lowering with atorvastatin, for instance, ranges from 14 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Rosuvastatin is also more effective in raising HDL-C levels than atorvastatin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of statin therapy are additive to those of a controlled diet. As an example, one study randomized 120 men with hypercholesterolemia to a usual diet or a modified Mediterranean diet rich in omega-3 fatty acids, fruits, vegetables, and dietary fibers; each group was further randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20 mg) or placebo and after 12 weeks crossed over to the alternate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/58\">",
"     58",
"    </a>",
"    ]. After 24 weeks, the reduction in LDL was greater with diet and drug (41 versus 30 and 11 percent for drug and diet alone); a similar additive effect was seen on triglyceride, HDL-C, and apolipoprotein B and A1 levels.",
"   </p>",
"   <p>",
"    Adverse reactions occur less frequently with the statins than with some other classes of lipid-lowering agents. Muscle injury is an important concern, primarily in patients who are also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or a fibrate; the excess risk appears to be eliminated by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , which are not metabolized by CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fibrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major effects of the fibrates are to lower plasma triglyceride and raise HDL-C levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. They are effective for the treatment of hypertriglyceridemia and combined hyperlipidemia with or without hypoalphalipoproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/59\">",
"     59",
"    </a>",
"    ]. There is an increased risk of muscle toxicity in patients taking some fibrates and a statin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Nicotinic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotinic acid is effective in patients with hypercholesterolemia and in combined hyperlipidemia associated with normal and low levels of HDL-C (hypoalphalipoproteinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The HDL raising properties of nicotinic acid occur with dosages as low as 1 to 1.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/62\">",
"     62",
"    </a>",
"    ]. In contrast, while modest VLDL-C and LDL-C lowering effects can occur at doses of 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    doses above this amount (3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    often produce greater effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/52,61\">",
"     52,61",
"    </a>",
"    ]. The use of nicotinic acid is often limited by poor tolerability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ezetimibe",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     Ezetimibe",
"    </a>",
"    modestly lowers the LDL-C when used alone and may be helpful for avoiding high doses of statins (and potentially increased susceptibility to muscle injury) in patients who do not meet cholesterol goals on statin therapy alone. However, the clinical benefits of either ezetimibe monotherapy or combining ezetimibe with statin therapy remain to be proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bile acid sequestrants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile acid sequestrants are effective in patients with mild to moderate elevations of LDL-C. Low doses (8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    or 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    ) can reduce LDL-C by 10 to 15 percent. A more pronounced reduction (about 24 percent) can be achieved at maximal recommended doses (24 and 30",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    respectively). A similar reduction in LDL cholesterol can be achieved with 1.5 to 4.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     colesevelam",
"    </a>",
"    . Bile acid sequestrants are also effective when used in combination with a statin or nicotinic acid in patients with markedly elevated plasma levels of LDL-C (",
"    <a class=\"graphic graphic_figure graphicRef63912 \" href=\"UTD.htm?40/17/41246\">",
"     figure 6",
"    </a>",
"    ). The use of a bile acid sequestrant is often limited by side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Success rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite awareness of the target LDL-C levels recommended by the National Cholesterol Education Program, lipid management is not optimal. As an example, one study of 4888 dyslipidemic patients from five regions in the United States found that, overall, only 38 percent achieved ATP II target LDL-C levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/63\">",
"     63",
"    </a>",
"    ]. Success rates were 68 percent among low-risk patients (no evidence of CHD and less than two risk factors), 37 percent in high-risk patients (no evidence of CHD and two or more risk factors), and 18 percent among those with CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Monitoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reliable data on the optimal method of monitoring the effects of lipid-lowering therapy. ATP III recommends that the LDL-C be monitored every six weeks after the initiation of treatment until the LDL-C target is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"     1",
"    </a>",
"    ]. Thereafter, measurement every 6 to 12 months is reasonable in patients adherent to lifestyle modifications.",
"   </p>",
"   <p>",
"    With statins in particular, lipids levels stabilize within several weeks (with some variation with particular statins) after a change in dose, and so checking lipid levels six weeks after a dosage change should provide a reliable result. As discussed elsewhere, however, the beneficial effects of statins appear to occur sooner than can be explained by changes in LDL-C, and with discontinuation may reverse more quickly as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\", section on 'Timing and mechanisms of benefit'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'PROVE IT-TIMI 22 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One analysis suggested that, given the gradual long-term increases in LDL-C with age and short-term variability in cholesterol measurements, monitoring lipid levels every three to five years might be superior to more frequent monitoring in adherent patients with well-controlled lipid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of individual patient data from the treatment arms of trials of statin therapy found an association between achieved lipid values (including LDL-C, non-HDL-C, and apolipoprotein B) and risk of major CV events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/32/26122/abstract/66\">",
"     66",
"    </a>",
"    ]. While it is not surprising that these achieved lipid parameters correlate with CV risk, the clinical application of the information from this analysis is limited as the data come from multiple trials with differing doses of statins, inclusion criteria, and baseline characteristics. When to modify therapy based on lipid response is controversial and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H10#H10\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Putting the evidence together'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our recommendations for secondary prevention are based upon data subsequent to ATP-III and are more aggressive than those of ATP-III, but less aggressive than some proposed modifications to ATP-III. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that all patients with an LDL-C above goal undergo lifestyle modifications in an effort to reduce the serum cholesterol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These modifications include diet and exercise. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"       \"Lipid lowering with diet or dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are given drug therapy should almost always be treated with a statin. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with CHD or a CHD equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"       table 4",
"      </a>",
"      ) who can tolerate statin therapy, we suggest treatment with at least a moderate dose of a statin (eg, 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , or 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      )",
"      <strong>",
"       independent of the baseline LDL-C",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). That is, even if a patient&rsquo;s baseline LDL-C is below goal or is close to goal such that a low dose of a statin would be expected to reduce the LDL-C below the ATP-III goal, we would initiate a statin and choose a moderate dose of a statin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H10#H10\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Putting the evidence together'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The appropriate goal LDL-C in patients with CHD or CHD equivalents being treated for secondary prevention is controversial and is discussed in additional detail separately. The below goal-based recommendations assume that, as discussed above, patients with CHD or a CHD equivalent will be treated with at least a moderate dose of a statin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that patients with an acute coronary syndrome be treated with intensive statin therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"       \"Cholesterol lowering after an acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients at very high risk for CHD events such as those in the proposed NCEP guidelines (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 3",
"      </a>",
"      ) might also be expected to benefit from more intensive lipid-lowering therapy. We suggest that such patients be treated with a dose of a statin that reduces their LDL-C at least below 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If such patients cannot achieve an LDL-C below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with a statin alone, we suggest the addition of a second lipid-lowering agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other experts, including other authors for UpToDate, would make differing recommendations regarding the need for a second agent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the increased side effects with more intensive statin therapy, and the lack of benefit on all-cause mortality, we suggest that, except in the highest-risk patients (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 3",
"      </a>",
"      ), patients with stable CHD or a CHD equivalent be treated with a dose of statin that reduces the LDL-C to less than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, more aggressive LDL-C lowering treatment to slightly reduce nonfatal cardiovascular events is a reasonable option in patients for whom the additional therapy would not impose undue burdens from side effects or cost. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H10#H10\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Putting the evidence together'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of clear evidence, we suggest that patients with stable CHD who do not tolerate a statin be treated with another lipid-lowering agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although the evidence also does not allow a clear answer on whether to add a second agent in usual risk patients with stable CHD who are unable to achieve their goal LDL-C with a statin alone, we suggest the use of a second agent in such patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other experts, including other authors for UpToDate, would make differing recommendations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link&amp;anchor=H11#H11\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Use of medications other than statins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/2\">",
"      Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009; 26:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/3\">",
"      Buyken AE, von Eckardstein A, Schulte H, et al. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil 2007; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/4\">",
"      Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/5\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/6\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/7\">",
"      Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/8\">",
"      Sever PS, Dahl&ouml;f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/9\">",
"      Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/10\">",
"      Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA 1999; 282:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/11\">",
"      Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/12\">",
"      Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 1996; 156:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/13\">",
"      Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/14\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/15\">",
"      Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/16\">",
"      Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/17\">",
"      Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/18\">",
"      Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997; 95:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/19\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/20\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/21\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/22\">",
"      Johannesson M, J&ouml;nsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997; 336:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/23\">",
"      Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/24\">",
"      Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/25\">",
"      Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994; 308:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/26\">",
"      Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/27\">",
"      Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/28\">",
"      Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. QJM 2004; 97:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/29\">",
"      Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/30\">",
"      Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/31\">",
"      Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/32\">",
"      Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/33\">",
"      Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996; 156:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/34\">",
"      Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999; 159:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/35\">",
"      Redberg RF. Don't assume women are the same as men: include them in the trial. Arch Intern Med 2012; 172:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/36\">",
"      Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012; 172:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/37\">",
"      Taylor F, Ebrahim S. Statins work just as well in women as in men. Arch Intern Med 2012; 172:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/38\">",
"      Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ 2012; 344:e1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/39\">",
"      Butowski PF, Winder AF. Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. Eur Heart J 1998; 19:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/40\">",
"      Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/41\">",
"      Stefanick ML, Mackey S, Sheehan M, et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998; 339:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/42\">",
"      Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/43\">",
"      Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/44\">",
"      Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine- or butter-based diet: A study in families. JAMA 2000; 284:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/45\">",
"      Henkin Y, Shai I, Zuk R, et al. Dietary treatment of hypercholesterolemia: do dietitians do it better? A randomized, controlled trial. Am J Med 2000; 109:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/46\">",
"      Hsia J, Rodabough R, Rosal MC, et al. Compliance with National Cholesterol Education Program dietary and lifestyle guidelines among older women with self-reported hypercholesterolemia. The Women's Health Initiative. Am J Med 2002; 113:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/47\">",
"      Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/48\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/49\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/50\">",
"      Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994; 78:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/51\">",
"      Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87:III45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/52\">",
"      Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med 1994; 154:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/53\">",
"      Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/54\">",
"      Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/55\">",
"      Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/56\">",
"      Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/57\">",
"      Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/58\">",
"      Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002; 287:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/59\">",
"      Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998; 81:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/60\">",
"      Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/61\">",
"      Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/62\">",
"      Probstfield JL, Hunninghake DB. Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med 1994; 154:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/63\">",
"      Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/64\">",
"      Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/65\">",
"      Glasziou PP, Irwig L, Heritier S, et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/32/26122/abstract/66\">",
"      Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307:1302.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4550 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-BFBE39938F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26122=[""].join("\n");
var outline_f25_32_26122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF PATIENTS AT RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1033672373\">",
"      Diabetes mellitus as a CHD equivalent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intensity of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264877640\">",
"      - Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cost-effectiveness of cholesterol-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Safety of cholesterol lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Specific groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment in diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treatment in the elderly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment in patients with familial hypercholesterolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Patients with low HDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Patients with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1480759365\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H611789608\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fibrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Nicotinic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ezetimibe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bile acid sequestrants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Success rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Monitoring therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4550\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4550|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/34/25134\" title=\"figure 1\">",
"      Simvastatin major cardiac event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/55/19325\" title=\"figure 2\">",
"      Simvastatin and CHD mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/30/24045\" title=\"figure 3\">",
"      Pravastatin CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/44/14030\" title=\"figure 4\">",
"      Statin benefits in HPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/34/6703\" title=\"figure 5\">",
"      Comparison statin drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41246\" title=\"figure 6\">",
"      Effects combined statin resin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4550|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10206\" title=\"table 1A\">",
"      Framingham ATPIII score men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/17/8478\" title=\"table 1B\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/20/333\" title=\"table 2\">",
"      Regression of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11147\" title=\"table 3\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/30/44523\" title=\"table 4\">",
"      CHD risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2795\" title=\"table 5\">",
"      Non HDL cholesterol goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/16/41227\" title=\"table 6\">",
"      Therapeutic lifestyle diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/1/28701\" title=\"table 7\">",
"      Types of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/47/22268\" title=\"table 8\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/30/14829\" title=\"table 9\">",
"      Properties of statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 10\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28570?source=related_link\">",
"      Determinants and management of cardiovascular risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10760?source=related_link\">",
"      Treatment of dyslipidemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_32_26123="Dx of alcoholic liver disease";
var content_f25_32_26123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACG guideline for the diagnosis of alcoholic liver disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        All patients should",
"be screened for alcoholic liver disease. A thorough history of alcohol",
"use should be obtained. The CAGE questionnaire is a useful screening",
"method for alcohol abuse or dependency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A detailed physical examination should be done, searching for signs of chronic liver disease and staging its severity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A liver chemistry",
"profile (including serum albumin, bilirubin and transaminases",
"[AST/ALT]). A complete blood count and prothrombin time or INR should",
"be obtained to support a clinical suspicion of alcoholic liver disease",
"and to assess its severity. However, both laboratory abnormalities and",
"physical findings may be minimal or absent even in patients with",
"established alcoholic liver disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When evaluating a",
"patient for alcoholic liver disease, the clinician must remember that",
"the toxic daily threshold dose of 80 g of alcohol is not absolute.",
"Elevations in serum ALT may develop at much lower doses, especially in",
"women and patients with hepatitis C infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It may be necessary",
"to perform a liver biopsy in patients with suspected alcoholic liver",
"disease when the diagnosis is unclear because of atypical features or",
"possible concomitant disease.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From the American College of Gastroenterology with permission. Recommendations for the diagnosis of alcoholic liver disease. Am J Gastroenterol 1998; 93:2022.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26123=[""].join("\n");
var outline_f25_32_26123=null;
var title_f25_32_26124="Choosing between mastectomy and lumpectomy PI";
var content_f25_32_26124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Choosing between mastectomy and lumpectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mastectomy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lumpectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        How will I look?",
"       </td>",
"       <td>",
"        If you decide not to have your breast reconstructed, you will have a scar where your breast used to be. If you do have your breast reconstructed, you will have a new breast made of an implant or out of skin, muscle, and fat taken from other parts of your body. Reconstructed breasts do not have as much sensation as breasts that have had a lumpectomy.",
"       </td>",
"       <td>",
"        Your breast will have a scar and might have a dent or dimple where the tissue was removed. The treated breast might be a little smaller than the other breast. Still, it will feel more like a real breast than a reconstructed breast and have more sensation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What will my recovery from surgery be like?",
"       </td>",
"       <td>",
"        <p>",
"         You will stay in the hospital for 1 to 2 days (or a little longer if you have reconstruction done, too). You will go home with drains that must be emptied twice a day and that stay in for about 2 weeks.",
"        </p>",
"        <p>",
"         Your recovery will take 4 to 6 weeks. During that time you will need to rest and avoid sports, swimming, and heavy lifting. You might need physical therapy.",
"        </p>",
"       </td>",
"       <td>",
"        You will go home from the hospital the same day as your surgery, and your recovery will take 1 to 2 weeks. During that time, you will need to rest and avoid sports, swimming, and heavy lifting. You might need physical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What are the risks or side effects of this surgery?",
"       </td>",
"       <td>",
"        Mastectomy is usually safe, but it can sometimes lead to bleeding, infection, or fluid build-up. Plus, the surgery can sometimes damage the skin on the chest. (This is more common in women who smoke.)",
"       </td>",
"       <td>",
"        Lumpectomy is usually safe, but it can sometimes lead to bleeding, infection, or fluid build-up where the cancer was removed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will I need more than 1 surgery?",
"       </td>",
"       <td>",
"        Possibly, if you decide to have your breast reconstructed later.",
"       </td>",
"       <td>",
"        Possibly, if the cancer comes up to the margins and the surgeon has to take more tissue.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will I need radiation therapy?",
"       </td>",
"       <td>",
"        Probably not. But some women who have mastectomy do need radiation.",
"       </td>",
"       <td>",
"        Yes. After lumpectomy, most women must have radiation therapy 5 days a week for 3 to 6 weeks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What are the chances that cancer will come back in the same area?",
"       </td>",
"       <td>",
"        Cancer can still recur after mastectomy because all the breast tissue cannot be totally removed. About 5 out of 100 women who have a mastectomy will have cancer come back on the chest wall after mastectomy.",
"       </td>",
"       <td>",
"        Fewer than 10 out of 100 women who have a lumpectomy will have cancer recur.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26124=[""].join("\n");
var outline_f25_32_26124=null;
var title_f25_32_26125="Causes of chronic diarrhea in children";
var content_f25_32_26125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of chronic diarrhea in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional diarrhea (chronic nonspecific diarrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive intake of juice/osmotically active carbohydrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate dietary fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Enteric infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Postenteritis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Parasites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giardia lamblia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptosporidia parvum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclospora cayetanensis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isospora belli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microsporidia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Entamoeba histolytica",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strongyloides, Ascaris, Tricuris spesies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroaggregative E. coli (EAggEC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteropathogenic E. coli (EPEC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterotoxigenic E. coli (ETEC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroadherent E. coli (EAEC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium avium complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Salmonella, Shigella, Yersinia, Campylobacter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rotavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteric adenovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Astrovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Torovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human Immunodeficiency Virus (HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syndromic persistent diarrhea (common in developing countries)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated with malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immune deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary immune deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary immune deficiencies (HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abnormal immune response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food allergic enteropathy (dietary protein-induced enteropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune enteropathy (including IPEX)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft vs Host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory bowel disease (more common in developed countries)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative Colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early onset inflammatory bowel disease (ulcerative colitis or Crohn's disease presenting prior to six years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Protein losing gastroenteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphangiectasia (primary or secondary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other diseases affecting the gastrointestinal mucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital persistent diarrhea (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microvillus inclusion disease (Microvillus atrophy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal epithelial dysplasia (Tufting enteropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital chloride diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital sodium diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital disaccharidase (sucrase-isomaltase, etc) deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital bile acid malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neuroendocrine tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrinoma (Zollinger-Ellison syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VIPoma (Verner-Morrison syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factitious diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laxative abuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manipulation of stool samples",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26125=[""].join("\n");
var outline_f25_32_26125=null;
var title_f25_32_26126="Lateral forearm";
var content_f25_32_26126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Lateral view of normal forearm in 9-year-old",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 173px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A true lateral view of the forearm has superimposition of the radial head upon the ulnar coronoid process at the proximal end, superimposition of the radius and ulna at the distal end, a view of the soft tissues around both bones, and an elbow position that is 90 degrees of flexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26126=[""].join("\n");
var outline_f25_32_26126=null;
var title_f25_32_26127="Peak pollen periods US PI";
var content_f25_32_26127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Peak pollen periods in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_32_26127=[""].join("\n");
var outline_f25_32_26127=null;
